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ABSTRACT




An efficient way of analyzing survival clinical data such as cancer data is a great con-
cern to health experts. In this study, we investigate and propose an efficient way of
handling survival clinical data. Simulation studies were conducted to compare perfor-
mances of various forms of survival model techniques using an R package “survsim”.
Models performance was conducted with varying sample sizes as small (n < 30), mild
sample (30 ≤ n ≤ 5000) and large sample (n > 5000). For small and mild samples,
the performance of the semi-parametric outperform or approximate the performance
of the parametric model. However, for large samples, the parametric model outper-
forms the semi-parametric model. We compared the effectiveness and reliability of
our proposed techniques using a real clinical data of mild sample size. Finally, sys-
tematic steps on how to model and explain the proposed techniques on real survival
clinical data was provided.
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1 INTRODUCTION
1.1 Background of the Study
Survival analysis is a collection of statistical methods that are used to describe,
explain, or predict the occurrence and timing of events. The study of survival analysis
became very famous in the early 1970’s. The outcome variable of interest is time until
an event occurs. The time may be measured in years, months, weeks, or days from
the beginning of follow-up of an individual/object until an event occurs. The term
event is used to mean death, disease incidence, relapse from remission, recovery (e.g.,
return to work) or any designated experience of interest that may happen to an
individual/object. The event of interest is sometimes called failure. For illustration
purposes, consider a study that follows lung cancer patients in remission over some
months to see how long a patient stays in remission. Here, the event of interest/failure
is “going out of remission”, the outcome is “time until the patient goes out of remission
and time is “months.”
In some survival studies, more than one event of interest (multiple events) can
occur or be considered. When more than one event occurs, the problem under study
is called recurrent event or competing risk problem. For example, the study of time
until an individual experiences a headache and stomach pain. The basic functions of
survival analysis are the same in all fields, but the name usually depends on the field
of study. For instance, in engineering it is called reliability analysis, in sociology it is
known as event history analysis, in economics it is famous with the name of duration
analysis and, as the name suggests, medical researchers give it the name of survival
13
analysis. In survival analysis, the time is called survival time.
The methods for handling survival analysis differ from other statistical methods
with the reasons that: time is always the response variable, there are possibilities of
staggered entries (the unit in the study have different time of entrance) which does
not affect survival analysis method since the method deals with the length of time of
observation and not based on the same entrance time and finally the assumptions of
normality does not hold since survival data are generally skewed.
Three main methods, namely, non parametric, semi-parametric and parametric
are usually used to analyze survival data. The methods give similar results but each
has its own unique procedure usually under specific assumptions or no assumptions.
In this study, we demonstrate that semi-parametric approach is robust among all
the three main methods used in survival analysis data. We consequently examine
the robustness under study through different sample sizes with varying amounts of
censored observations.
1.2 Problem Statement
Survival analysts especially clinicians, are usually on the look out for the “easiest”
way to analyze survival data. The study of survival analysis is moderately new with
limited software or software packages to handle some survival analysis approach [28]
particularly in the area of parametric survival studies. This problem tends to impede
which specific procedure to be used in analyzing survival data in practice. When sur-
vival analysts are just interested in examining the trend of occurrences of diseases or
to compare the efficacies of treatments, the non-parametric approach introduced by
14
Kaplan-Meier (KM) is usually used since no rigorous assumption is made. However,
in most cases, analyst would not just be interested in comparing but also to make a
mathematical prediction via modeling of survival data. Modeling, of course, tends to
be one of the most intensive/difficult and time consuming approaches in statistical
analysis. In the field of survival analysis, lack of statistical software/packages coupled
with intensive assumptions to handle some aspect of parametric distributions impede
its usage by most clinicians. In practice, few distributions such as Weibull, Expo-
nential, Log-logistics and Lognormal are usually used in parametric survival model.
Thus, this study tend to demonstrate/justify a way that can be used to handle sur-
vival data especially modeling clinical data through semi-parametric approach whiles
relying on less rigorous assumptions.
1.3 Objectives of the Study
The main objectives of the study are as follows:
• To show the robustness of semi-parametric approach among all the survival
analysis techniques.
• To compare the results of survival modeling techniques through model selection
approach.
• To learn an effective method specific to survival model techniques for survival
data.
• To provide some steps to analyze and model real survival clinical data using the
semi-parametric approach.
15
1.4 Scope of the Study
The study will cover the few parametric survival models used in practice such
as Weibull, exponential, log-logistics and lognormal distribution and semi-parametric
survival models proposed by [6, 7]. The other approach such as non-parametric (KM)
is of little concern and so may not be discuss in details.
1.5 Significance/Justification of the Study
Specific or alternative approach to survival modeling is mostly of concern. By the
end of this study, clinicians will be able to find an efficient way to model survival data.
We also hope this thesis will guide or raise the confidence of other survival analyst
in different field a better method to be used in modeling survival data. Finally, the
study also broadens the researcher knowledge in steps to handle survival data.
1.6 Materials and Method
We simulate various forms of survival data with varying sample size and censored
observations that follows a particular parametric models. We fit each of the simulated
data with semi-parametric and other forms of parametric models. We compare the
results through model selection procedure using Akaike Information Criterion (AIC)
and their standard errors. With similar approach, we fit a real data taken from
clinical data. We compare the results consistencies with the simulation results. The
results of the clinical data are further examine with graphical output. Conclusions
and recommendations are then made based on the research objectives. Throughout
the study, R - software version 3.5.1 were used.
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1.7 Limitation of the Study
Sometimes in survival study, more than one event is considered usually called
multiple event or recurrent event or competing risk problems. In this study, both
simulations and real data are limited to single event problems. For example, the
study of the time until a breast cancer patient die with the diseases. We however,
refer any interested reader to the work of [11] on multiple event problems.
1.8 Summary/Organization of the Study
To achieve expediency when reading, the study was organized in five main chapters
with sections and subsections. The first chapter covers the introduction of the study
with the following sections: background of the study, problem statement, objectives,
scope of the study, significant of the study, materials and methods, limitation and
organization of the study. Chapter two provides the literature review on conceptual,
empirical works and methods of previous researchers and limitation’s, simulations and
application to clinical data with pertinent references. Chapter three deals with the
mathematical formulations and procedure’s used in achieving the study. Chapter four
provides a critical analysis, presentation and interpretation of simulation studies and
real clinical data. Chapter five gives the conclusion part which involves discussion of
the results, conclusion, recommendation of the study and future direction.
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2 LITERATURE REVIEW
2.1 General Framework of Survival Analysis
The origins of survival analysis may be tracked from the study of mortality in
the seventeenth century. It has become one of the most frequently used methods
for analyzing data in many field from epidemiology, engineering, marketing and so
on. Some of the objectives of survival analysis include estimation, interpretation
and comparison of survival of groups. The primary variable in survival analysis is
survival time. The term “survival time” is used generally to mean the time until an
event of interest occurs. For example, the time until married couples divorce. One
special features of survival time is that it is a nonnegative random variable. The
second special feature is that the survival time always follows a skewed distribution.
Though, transformation can be applied to make the distribution more symmetric,
using a different model may be more satisfactory [16].
Survival analysis is special from any other statistical methods of analysis because
of some missing information during the study. Some of the experimental units may
not have experienced the event of interest before the study ends, study dropouts
and lose to follow up thereby making the dataset incomplete. This phenomenon of
incompleteness is termed as censoring. Censoring is group into right, left and random
censoring. For illustration of this phenomenon, consider figure 1 that study cancer
patients for eight weeks until patient’s die with the cancer. The event of interest
is death. The patients have staggered entries into the study i.e, the patients have
different entry time.
18
For right censoring, consider patients B, C, D, and E. The study ends (after 8
weeks) and B and D are still alive. Patients C did not show interest in the study and
so dropped out. The investigator were not able to track patient E and so was lost to
follow up.
Random censoring occurs when the death is not related to the study under con-
sideration. Suppose that both A and F had fatal car accident and died. The death
is not related to the study under consideration, i.e cancer.
Left censoring, the individual has already experience the event before enrolling
into the study but the exact time of first exposure in not known. Suppose that
a college counselor wants to study the time until newly admitted students smoke
cigarette before graduation. If a student has smoked before being admitted then that
student is left censored.
In all the illustrative examples, we do not know the individual/object exact sur-
vival time. The most widely used technique is right censoring.
19
Figure 1: Illustration of types of censoring
2.2 Approaches to Survival Analysis
2.2.1 Non Parametric Survival Function
The commonly used nonparametric method for estimation of the survival function
is the [10]. The nonparametric analyses is often used where there is doubt about the
exact form of distribution. The advantages and popularity of Kaplan Meier(K-M) is
its accessibility in most computer and statistical software. Also, the non-parametric
method makes no assumption about the distribution of the failure time. However,
using a non-parametric analysis typically generated much wider confidence bounds
than those calculated via parametric analysis. The K-M survival curve is the plot of
the Kaplan-Meier estimator of the survival function S(t) against time t. The graph is
a step function that decreases at every event time. In modeling of survival data the
20
K-M curve may give a hint about which model is more appropriate for a particular
data set. If the empirical survival curve behaves similarly to a particular parametric
distribution then this model may have a good fit to the data [4] and [14].
2.2.2 Semi-Parametric versus Parametric Survival Function
Which method is most accurate among the three methods of survival analysis is
still under battle especially in the studies of clinical data. Many researchers have
proposed which methods fits well in their research studies based on the underlying
assumptions. Parametric method assume that the time to event variable comes from
a specific distributional family. Based on asymptotic results, under certain circum-
stances, parametric models lead to more efficient parameter estimates. In the work of
[13] they indicated that when the underlying assumptions of the distribution follows
a known parametric distribution, the result has more power ( little variance) than
the semi parametric model and are easier to interpret.
Furthermore, parametric survival models estimate the survival function more pre-
cisely than the non-parametric method. Unfortunately, in real data, it is often hard
for a data to precisely follow a particular parametric distribution. The claim works in
simulation studies [21]. One main challenges in parametric approach is lack of avail-
ability of software [28] and in some cases, hard to be analyzed by many health experts,
biostatistician and statistician alike. Again, fully parametric models involve stronger
restrictive assumptions than semi-parametric. There are many forms of paramet-
ric distribution in statistics but few such as Weibull, Exponential, Log-logistic and
lognormal are commonly used and tested for survival models in many books and lit-
21
erature. Researchers typically want to know how well their statistical models fit the
data. Comparisons of model selection can be accomplished with Akaike’s information
criterion (AIC) or Schwarz’s Bayesian Information Criterion (SBC or BIC). Usually,
the AIC is used to select the best model among the few parametric model specified
[25]. Following the concern of [28] it is clear that given availability of software to
handle almost all the parametric models, the best model that is commonly selected
by AIC as best among the few parametric models used in literature may not even
worth selected as best. In most cases, the best model selected by AIC do not satisfy
its underlying distribution assumption. These problems, commonly make parametric
approach of little use in practice.
Again, though fully parametric survival models under certain circumstances may
lead to more efficient parameter estimates than both nonparametric and semi-parametric
models [20], they are not often used in the analysis of medical studies of survival as
they involved stronger assumptions which may make them more prone to danger of
model misspecification than the semi-parametric model.
The semi-parametric model is another approach in survival model. The well know
semi-parametric survival analysis model is the [6, 7]. This approach is commonly
used by survival analyst in analyzing clinical data [1]. The Cox model focuses di-
rectly on the hazard function with a mild assumptions about the baseline hazard
function. That is, the semi-parametric nature of the Cox regression, although based
on a parametric regression model, it does not make specific assumptions about the
probability distribution of the event time.
The hazard and the probability of survival are interrelated; the relationship may
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be complex, but sufficient to be able to determine a parameter with the other. Thus,
given the survival function S(t), we can obtain the corresponding hazard function
λ(t) and vice versa. The main assumption of semi-parametric model is that hazard
is proportional. In the case where the hazard is not proportional, [7] proposed a
method generally called extended Cox model, a means to handle non proportionality
assumption by including time dependent covariate or using stratification. The Cox
model tends to be “robust” so that the results from using the Cox model is closely
approximate the results for the correct parametric model [13]. In a study by [20], they
analyzed four different kinds of clinical data and the results shows that in most cases
the semi-parametric and parametric results were similar. Many forms of robustness
has been discussed and details can be found in the works oF [17] and [15].
To avoid increased efforts with model checking and because dangers of misspeci-
fication are assumed to increase with parametric survival models, clinicians tend to
prefer Cox’s model. The proportional hazards regression model is very popular due
to the easy concept and accessibility of software [3].
2.3 Application of Survival Analysis with Reference to Clinical Data
The term survival analysis is predominant in the field of medicine. The main
objective in the study of survival analysis in clinical trials is often to compare the
performance of treatments or the survival differences of two or more groups, see for
example the work of [16]. In order to investigate the comparative performance of Cox
and parametric survival models under the typical conditions of clinical studies, either
some samples of simulations or by means of real data sets is used. For instance, in the
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study of the comparison of Cox and parametric models in clinical studies, [20] used
real data where they studied four different clinical data on lung cancer, infections
after heart transplantation, breast cancer and liver transplant with different sample
sizes ranging from 217 and 526, in some cases the cox provides similar results to the
parametric models. They also compared the results with parameter variability.
Figure 2: Steps for analyzing survival clinical data
2.4 Simulation Study
Simulating a data to check the performance of a particular techniques in survival
analysis has gained root in recent studies because of the rapid growth in the study
area as well as accessibility of software. Simulation studies, uses computer intensive
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procedures to assess the performance of a variety of statistical methods and evaluating
the properties of the model. The generation of survival data is the most fundamental
and important component in the simulation of clinical study. However, few published
articles are available in literature which make use of the simulation of complex survival
data, one possible reason being a lack of easily used tools facilitating such simulations.
One popularly used software for generating simulations of clinical data is R. In R,
there are a lot of functions for survival analysis in the package “survival”. In recent
study, [19] wrote some packages for R and outlined the procedure for generating
clinical data. This thesis explore the usage of the packages and procedures suggested.
A comprehensive techniques for simulation of survival data is given by [18] and
[24].
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3 METHODOLOGY AND MATHEMATICAL FORMULATION
3.1 Survival Function
Let T be the random variable representing survival time of a subject, the survival
function S(t), is defined as the probability that an individual survive beyond time t.
It is given by:
S(t) = P (T > t), 0 ≤ S(t) ≤ 1 (1)
3.2 Properties of Survival Function
1. It is decreasing function.
2. At time t = 0, S(t)=1
3. At time t =∞, S(t) = 0. As time goes to infinity, the survival curve goes to 0.














f(u)du,∀t ∈ [0,∞] (3)
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3.2.1 Relationship between Survival Function and Cumulative Distribution Function
Let f(t), t ≥ 0, denote the probability density function (pdf) of T and F (t) =
P (T ≤ t) =
∫ t
0
f(u)du, t ≥ 0 be the cumulative distribution function (cdf) of T, then
S(t) = P (T > t)
= 1− P (T ≤ t)
= 1− F (t)
Taking the differential of both sides
(4)
S ′(t) = −F (t)
= −f(t)
(5)
3.2.2 The Hazard Function
The hazard function λ (t), is a measure of the probability of failure during a
very small interval, assuming that the individual has survived at the beginning of the
interval. it is defined mathematically as:
λ(t) = lim
Ot→0
P (an individual who survive to time t fail in(t, t+ Ot))
Ot
(6)
λ(t) has two major properties: it is always nonnegative and has no upper bound. The







The cumulative hazard Λ(t), and the hazard function λ(t), for discrete random vari-





3.2.3 Discrete Random Variable of Survival Function
If the failure time is discrete then:
λ(aj) = λj = P (T = aj|T ≥ aj)
=
P (T = aj)





3.2.4 Continuous Random Variable of Survival Function










P ([t ≤ T < t+ Ot] ∩ [T ≥ t])





P ([t ≤ T < t+ Ot])















Λ(t) = −logS(t) (13)
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Equation (14) gives the relationship between cumulative hazard and the survival
function whiles equation (15) gives the relationship between hazard function and the
survival function. Thus given any one of three functions S(t), Λ(t) and f(t) , the
others two can be derived.
3.2.5 Estimation of Survival Function
The are two ways of estimating survival function and the hazard function.
1. By specifying a parametric model for S(t) bases on a particular density function
f(t)
2. By developing an empirical estimate of the survival function (i.e., non-parametric
estimation)
If there is no censoring, the empirical estimate of the survival function S(t), is pro-
portion of individuals with event times greater than t.
S(t) =
number of individuals with failure time greather than t
total sample size
(16)
When there is censoring, equation (16) loses its power to estimate S(t) because the
numerator can no longer be estimated.
There are three techniques in describing survival data that contain censoring. These
are non parametric ( Kaplan Meier), semi-parametric (usually called the Cox Pro-
portional Hazard) and parametric.
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3.3 The Non-Parametric Method (Kaplan-Meier Estimator)
The important assumption of the Kaplan-Meier (KM) survival function is that
the distribution of censoring times is independent of the exact survival times. The
estimated survival probabilities are computed using a product limit formula with
the log-rank test used to compare two or more survival groups and the variance
estimated using the Greenwood’s formula. The test statistic for the log-rank test
is a bit complicated mathematically especially comparing more than two groups so
usually a computer software is used. We present a brief method of estimating KM
survival function. We refer interested reader in log-rank test and variances to [14]
and [27].
3.3.1 Estimating Kaplan-Meier Estimator
Consider the conditional probability:
P (A1|A2) =





, P (A2) ≥ 0
(17)
The general multiplication rule for event A1, A2 and A3:
P (A1 ∩ A2 ∩ A3) = P (A1).P (A2|A3).P (A3|A1 ∩ A2) (18)
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But P (T ≥ a1) = 1− P (T < a1)
If S(t) is the survival time such that ak ≤ t ≤ ak+1, t ∈ (ak, ak+1) then,
S(t) = P (T ≥ ak+1)
= P (T ≥ a1, T ≥ a2, · · · , T ≥ ak+1)
= P (T ≥ a1)
k∏
j=1
P (T ≥ aj+1|T > aj)
























dj is the number of individual who fail in the jth interval
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rj is the number at risk right before the j
th failure time and beyond (including censored
observation)
3.4 Semi- Parametric Model
3.4.1 Cox Proportional Hazard Model (Cox PHM)
Cox emphasize more on the hazard function than the survival time.
Suppose that the data taken on n subject are denoted by (ti, δi, Zi), where ti is the
failure time of the ith subject, δi is the failure indicator such that for the ith subject
δi = 1 if a subject is observed to failure and δi = 0 otherwise and Zi = (Zi, · · · , Zp)
is p-dimensional vector of covariate. We can estimate the parameters β which reflect
the effects of treatment and other covariates without having to make any assumptions
about the form of λo(t). In other words, we don’t have to assume that λo(t) follows
an exponential model, or a Weibull model, or any other particular parametric model.
Let
λ(t, Z) = λoψ(Z) (22)
We can write the second term as ψ(Z) = exp(βZ)
Suppose Z = 1 for treatment subject and Z = 0 for untreatment subject.
Then this model compares increase by a factor exp(β) for treatment subject verses
untreatment subject. The Cox proportional hazard model assume that the hazard
function λ(t) for the ith subject with covariate value Zi has the following form
λ(t, Z) = λ0(t)exp(β
′Z) (23)
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Where λ0(t) is an unspecified baseline hazard function reflecting the underlying haz-
ard for subjects with all covariate Z1, Z2, · · · , Zi equal 0. (i,e reference group) and
β is a p -vector of unknown regression coefficient. The model 3.23 is referred as a
semi-parametric hazard function because the dependence function exp(β′Z) can be
modeled explicitly but no specific probability distribution is assumed for the survival
time.
For illustration purpose, consider a categorical variable with two levels (say X= 1,
for treatment group and X= 0 for placebo), then the hazard ratio (HR), for th two





When HR = 1, then the individuals in the two categories are at the same risk of
getting the event, HR > 1, the individuals in the first group (X=1) are at higher risk
of getting the event and if HR < 1, the individuals in the second group (X= 0) are
at a high risk of getting the event.
3.4.2 Method of Estimation
Suppose X1, . . . , Xn be n possible right censored failure times and Z1, . . . , Zn be
the corresponding covariate vectors where Zi is observed on [0, Xi]. Let the censoring
be assumed to be non informative. Then under the Cox proportional hazard model
(Cox PHM), the estimation of the regression coefficients β can be found by using the
partial likelihood estimation of Cox model which is a product over the set of observed
death times of the conditional probability of seeing the observing death, given the set
of individual at risk at those times.
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At each death time Γj , the contribution to the likelihood is
Lβ =
P (individual j fails|at risk at Γj)∑




Under the PH assumption :












Therefore given a sets of covariates Zi = (Z1i, Z2i, . . . , Zpi) we can model their hazard
rates as some multiple of the baseline hazard rate
λi(t, Zi) = λo(t) exp(β1Z1i, β1Z2i, . . . , β1Zpi)




) = β1Z1 + β2Z2 + · · ·+ βpZp (26)
The Cox PHM is a linear model for the log of the hazard ratio.
3.4.3 Assumption of Cox PH
• The baseline hazard depends on time t, but not on the covariates.
• The hazard ratio, i.e., exp(βZ), depends on the covariates but not on time t.
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3.4.4 Checking Cox PH Assumption
There are several options for checking the assumption of proportional hazards:
1. Graphical Method
• Plot of the survival estimates for two subgroup
• Plots of log[-log(S)] versus log(t) for two subgroups.
• Plots of observed survival probabilities versus expected under PH model
2. Use of goodness of fit test
We can construct a goodness-of-fit test based on comparing the observed survival
probability with the expected under the assumption of proportional hazards.
3. Including Interaction terms between a covariate and time t
Time dependent covariates. If the covariate is continuous, break into categories.
3.4.5 What to do when Cox PH assumption is rejected
• Examine the structural form of the predictors in the model. Perhaps they have
a more complicated relationship with the log hazard.
• Repeat the analysis by stratifying on the exposure variable. If there are no other
predictors of interest then do not fit any model, just obtain Kaplan-Meier curves
for each exposure group separately. If there are additional control variables fit
a Cox model in which the levels of the exposure variable are treated as strata.
• Start the analysis at a time when the PH assumption appears to hold, and use
a Cox PH model for only those individuals that survived that long.
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• Fit a modified Cox model that includes a time-dependent variable that incorpo-
rates the interaction of exposure with time. Such a model is called an extended
Cox model.
• In the worst scenario, switch to a parametric model.
3.5 Parametric Survival Model
3.5.1 Accelerated Failure - Time Models
The parametric models use the Accelerated Failure Time (AFT) model for esti-
mating univariate survival censored data. In the AFT model more attention is given
to the survival time than to hazard function. The AFT model means that the survival
function of an individual with covariate X at time t is the same survival function of an
individual with a baseline survival function at a time exp(βtX)t where βt is a vector
of regression coefficients. It means
S(t|X) = S0[exp(βtX)t]for all t (27)
where exp(βtZ) is called an acceleration factor. The acceleration factor allows to
evaluate the effect of predictor variables on survival time. That is, how a change in
covariate alters the time scale from the baseline time scale. It also implies that the
median time to event with covariate X is the baseline median time to event divided by
its acceleration factor. Similarly, the hazard function is also calculated. It is related
to the baseline hazard rate.
λ(t|X) = λ0[exp(βtX)t] exp(βtX), for all t (28)
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In general, for linear regression model, the response variable is given by
Ti = β
′Xi + εi (29)
If the response variable Ti in equation (29) is now replace by log Ti, the resultant
model is called the AFT model. That is:
logTi = β
′Xi + εi (30)
Where X ′is are the independent variable’s (covariate’s),
β′ are constants to be determined and
εi is the error term.
The role of the covariates in the above equation is to accelerate (or decelerate) the time
to failure. The error term εi, is assumed to be independent and identical distributed
with mean zero. The various choice of εi distribution lead to the regression version
of different parametric survival models. For the log transformation of T, its main
purpose is to ensure that predicted values of survival time T, are positive, regardless
of the values of the x’s and the β′s. Equation (30) is referred to as the parametric
model if the distribution of baseline hazards function is specified and if not; it is called
a semi parametric model.
If a parametric model has just n scale parameter λ, that parameter is replaced by:
λ = exp(−α0 − α1x1 − α2x2 − α2x3 − · · · − αnxn)





The general form of the AFT model in terms of the survival time T is





AFT model is multiplicative in terms of T and additive in terms of log(T ). For sim-
plicity and interpretation, the time ratio(TR), which is the exponentiated regression
coefficients (exp(β)) , is recommended to express in the same way hazard ratio (HR)
is interpreted in the models of proportional hazards. When TR > 1 for a covariate
indicates a slow down or prolongs the time to event and TR < 1 for a covariate sug-
gests the occurrence of earlier event is more likely [12].
One assumptions of the parametric model is that the survival time is assumed to
follow a distribution with density function f(t). Exponential, Weibull, Log normal,
Log-logistic are the most familiar survival distributions. We discuss the various AFT
models below.
3.5.2 The Exponential Distribution
The exponential distribution is a parametric distribution with only one parameter.
In exponential distribution, hazard function is assumed to be constant over time.
Consider the density function f(t), given by:
f(t) = λ exp(−λt) (33)







The above equation (34) gives the survival function for a survival data that follows
an exponential equation.
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To check if the exponential model is appropriate,
Take log of both side of equation (34):
logS(t) = −λt (35)
A graph of Kaplan Meier survival estimate of logS(t) against time t, should produce
approximately straight line with negative slope if the exponential assumption or model
is valid.






From equation(7), the cumulative hazard is estimated as:
Λ(t) = − logS(t)
= λt
(37)
The exponential proportional hazard and acceleration failure time are the same model
except that the parameterization is different.
3.5.3 The Weibull Distribution
The Weibull model is a parametric distribution with two parameters. The Weibull
model is a slight modification of the exponential model. The model is obtain if the
error term ε has an extreme value distribution with the following density: fε(x) =
exp(x− expx),−∞ < x <∞
Equivalently, T has the Weibull distribution with the following density:
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f(t) = λk(λt)(k−1) exp(−(λt)k), t ≥ 0.







The above equation (38) gives the survival function for a survival data that follows a
Weibull model. To check if the Weibull model is appropriate, take.
log of both side of equation (38):
logS(t) = −(λt)k (39)
log(− logS(t)) = k log λ+ k log (40)
A straight line in the plot of log(− logS(t)) vs. log t indicates a Weibull model. We
can use the above equation to check if the Weibull model is a reasonable choice for
the survival time given a data set.
Alternatively, we can assume a Weibull model for the survival time and use the data
to estimate S(t) and plot this estimate against the Kaplan-Meier estimate as proposed
for the exponential distribution. A (approximate) straight line indicates the Weibull
model is a reasonable choice for the data.







The cumulative hazard is estimated as:
Λ(t) = − logS(t)
= (λt)k.
(42)
where λ and k are the scale and shape parameter respectively. The Weibull distribu-
tion is convenient because of its simple form. it includes several hazard shapes:
k = 1 means constant hazard, 0 < k < 1 implies decreasing hazard and k > 1 implies
increasing hazard.
The Weibull distribution reduces to exponential distribution when k = 1.
The λ is a scale parameter in that the effect of different values of λ is just to change
the scale on the horizontal (t) axis, not the basic shape of the graph. This model
is very flexible and has been found to provide a good description of many types of
time-to-event data.
We might expect an increasing Weibull hazard to be useful for modeling survival
times of leukemia patients not responding to treatment, where the event of interest is
death. As survival time increases for such a patient, and as the prognosis accordingly
worsens, the patient’s potential for dying of the disease also increases.
We might expect some decreasing Weibull hazard to well model the death times of pa-
tients recovering from surgery. The potential for dying after surgery usually decreases
as the time after surgery increases, at least for a while.
3.5.4 Log-Logistic Distribution
The lifetime T is log-logistically distributed if Y = log(T ) is logistically distributed
with location parameter µ and scale parameter γ. Hence, Y is also of the form
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Y = µ+ γZ where Z is a standard logistic random variable with density
exp(z)
(1 + exp(z))2
,−∞ < z <∞
Equivalently, T has the log-logistic distribution with the following density:
f(t) = λk(λt)k−1(1 + (λt)k)−2, t ≥ 0, k > 0, λ > 0 (43)













Taking log of both side of equation (45) gives:
− log( S(t)
1− S(t)
) = k log λ+ k log t (46)
Similarly, a straight (approximately straight line) line in the plot of log t against
− log( S(t)
1− S(t)
) indicates a log-logistics model. We can use the above equation to
check if the log-logistics model is a reasonable choice for the survival time given a
data set.









From equation (47) above, the cumulative hazard is estimated as.
λ = − logS(t)




The log-logistic distribution is also characterized by two parameters. The shape
parameter k and the scale parameter λ.
The hazard function is identical to the Weibull hazard aside from the denominator
factor 1 + (λt)k .
For α < 1, it is monotone decreasing from ∞ and is monotone decreasing if λ = 1







The Log-normal has two parameter, scale parameter σ and shape parameter Γm








[ln t− ln Γm]), 0 < t <∞ (49)
The survival function is given as:













)([lnx − ln Γm])dx = Φ[
ln t− ln Γm
Φ
]andΦ(z) de-
notes the standard normal cumulative distribution function.


















3.5.6 Problem Associated With AFT Model
The main reason of the unpopularity of accelerated failure time model is:
• It is complicated estimation process, even if the data set consists of small number
of covariates.
• AFT is based on a parametric model, which may be difficult sometime to fit.
3.5.7 Models Selection
We fit various survival distribution functions to the data and visually compare
how similar the survival functions are to the Kaplan-Meier estimate of the survival
function. The graph of the distribution that is nearest to that of the Kaplan-Meier
estimate is the best model.
Another is to use either Bayesian information criterion (BIC) or Schwarz criterion
(also SBC, SBIC) or Akaike Information Criterion ( AIC) to choose the closest model.
For example, the AIC is give as, −2Log(maximum likelihood) + k × p, where p is
number of parameters in each model under consideration and k a predetermined
constant. For this study, we use the AIC to select the best model. In some case, we
use both method to select the model. Finally, we compare the standard variability of
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the covariates for each model.
3.6 Simulation Study
First, we perform a simulation study where we generate a purely parametric sur-
vival model for each of the commonly used survival analysis such as Weibull, Exponen-
tial and so on. We fit the simulated data for all the parametric and semi-parametric
model and compare the results by examining the average AIC (AIC) and average
BIC (BIC). We compare the results to the results obtained by [2].
Next, we simulate a purely semi-parametric model and fit the data with all the well
known parametric models. We expect that regardless of the best parametric model se-
lected by AIC and BIC, its variance will be greater than that of the semi-parametric
model. Finally we compare all the variances and AIC and BIC the simulated data
and relevant conclusion made. For time convenience, we simulate randomly 1000
different data samples, 500 different data samples and 50 different data samples for
each of small size, medium size and large size respectively and the averages of the




We use any arbitrary clinical data and fit it with all the semi-parametric model
and parametric and compare the performance. This is done to compare the results of
the simulation study and real clinical data. Finally, we provide some steps to analyze
real survival clinical data to fulfill research objective four.
3.8 Computer Software and Packages
Throughout this study, we use the R software which is an open source for the
results analysis. [19] presented an appealing R-packages for both simulation studies
of clinical data and its application to real clinical data. Thus, the analysis of the




We perform simulations to examine the performance of the techniques used in
survival studies. Throughout this study, we simulate a right censored survival data
which is commonly used in clinical studies. Many methods and algorithms have been
proposed for simulating a right censored survival data, see for example [5], [26], [29],
[9] and [19]. Though the works of [9] and [19] are available (with code in R), the
former focuses more on generating right censored data under the Cox model but the
latter focuses on generating parametric survival models for clinical data. Thus in this
study, we simulate data according to the procedure in the work of the latter.
4.1.1 Simulation Method and Sample Size
Most statistical studies define small sample size as any sample less than 30 and
any samples 30 and above as large. In the case of survival analysis, how large or small
samples must be is not well investigated. However, in the master’s thesis of [22], the
following samples (n=20, 100, 1000) were defined as small, moderate and large for
simulation studies to examine accuracies. In this study, we simulate any sample less
than 30 as small samples, between 30 and 5000 as medium sample and above 5000
as large samples. That is, n <30 as small samples, 30 ≤ n ≤5000 as medium sample
and n≥ 5000 as large samples.
In each of the models (parametric and semi-parametric), we investigate the per-
formance for small sample data, medium sample data and large sample data. For
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example, in exponential model, we examine performance by independently simu-
lating small and large samples where the underlying distribution follows an expo-
nential distribution. We highlight the R codes by [19] as follows: The function is
simple.surv.sim(n, foltime, dist.ev, anc.ev, beta0.ev, dist.cens = “weibull”, anc.cens,
beta0.cens, z = NA, beta = NA, x = NA)
The description of the arguments are:
• n: Integer value indicating the desired size of the cohort to be simulated.
• foltime: Real number that indicates the maximum time of follow-up of the
simulated cohort.
• dist.ev: Time to event distribution, with possible values “weibull”, for Weibull
distribution, “lnorm” for log-normal distribution and “llogistic” for log-logistic
distribution.
• anc.ev: Ancillary parameter for the time to event distribution.
• beta0.ev: β0 parameter for the time to event distribution.
• dist.cens: String indicating the time to censoring distribution, with possible
values “weibull” for Weibull distribution (this is the default value), “lnorm”
for log-normal distribution and “llogistic” for log-logistic distribution. If no
distribution is specified, the time to censoring is assumed to follow a Weibull
distribution.
• anc.cens: Real number containing the ancillary parameter for the time to cen-
soring distribution.
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• z: Vector with three elements that contains information relative to a random
effect used in order to introduce individual heterogeneity. The first element indi-
cates the distribution, where “unif” stands for a uniform distribution, “gamma”
stands for a gamma distribution, “exp” stands for an exponential distribution,
“weibull” stands for a Weibull distribution and “invgauss” stands for an inverse
Gaussian distribution. The second and third elements indicate the minimum
and maximum in the case of a uniform distribution (both must be positive)
and the parameters in the case of the rest of distributions. Note that just one
parameter is needed in the case of the exponential distribution. Its default value
is NULL, indicating that no individual heterogeneity is introduced.
• beta: List of vectors indicating the effect of the corresponding covariate. The
number of vectors in beta must match the number of covariates, and the length
of each vector must match the number of events considered. Its default value is
NA, indicating that no covariates are included.
• x: List of vectors indicating the distribution and parameters of any covariate
that the user needs to introduce in the simulated cohort. The possible distri-
butions are normal distribution (“normal”), uniform distribution (“unif”) and
Bernoulli distribution (“bern”). Its default value is NA, indicating that no co-
variates are included. The number of vectors in x must match the number of
vectors in beta. Each vector in x must contain the name of the distribution and
the parameter(s), which are: the probability of success in the case of a Bernoulli
distribution, the mean and the variance in the case of a normal distribution;
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and the minimum and maximum in the case of a uniform distribution.
4.2 Simulation of Parametric Results
To study the performance of different methods of survival analysis of clinical data,
we conducted series of simulations to access the performance of the methods used in
survival studies with varying sample cohort using the techniques described above.
The simulation study is divided into two cases. First, we consider the case where
the time to survival or event of patients do not depend on any covariate. Second, we
consider the case where time to survival or event of patients depend on covariate.
4.2.1 Simulation of Exponential Survival Data without Covariate
We simulated small sample of 12, medium samples of 250 and large samples of
30000 cohort where the time to censoring of an event is assumed to follow an expo-
nential distribution. Each of the small samples, medium samples, and large samples
were generated 1000 times, 500 times, and 50 times respectively. For each iteration
of the generated data set, the data set is fitted for all the methods. Finally, the
averages of the output of the results of the fitted model are calculated. That is, the
average values of the intercept, standard error, test statistic (z), p-value, AIC, and
BIC were calculated. The results of the fitted methods for each of the samples are
summarized in Table 1. Since the semi-parametric given by the Cox model explains
the ratio of covariates, the intercept value is not relevant. Thus, much of the emphasis
is placed on comparison of all the methods using two different model selection proce-
dure: average AIC (AIC) and average BIC (BIC). From table 1, we could see that
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the semi-parametric tend to perform well than all the parametric model for small and
medium sample by comparing the results of the average AIC and average BIC val-
ues, where smaller (AIC) and (BIC) value indicates better performance. Since the
underlying survival distribution follows the exponential distribution, the exponential
distribution outperforms all the parametric distribution in terms of the (AIC) and
(BIC) values.
However, when the samples is “extremely large” the semi-parametric model per-
forms poorly among all the methods whiles the exponential distribution outperform
all the methods being studied.
Table 1: Simulation of exponential Survival data (time to censorship follows expo-
nential without covariate)
Model sample(n) intercept Std.Error z p AIC BIC
12 N/A N/A N/A N/A 33.37969 33.37969
Cox 250 N/A N/A N/A N/A 1876.401 1876.401
30000 N/A N/A N/A N/A 461630.6 461630.6
12 5.894048 0.3233470 18.27889 7.2e-46 135.39336 135.87827
Exponential 250 5.837965 0.06957457 83.92166 0 2828.680 2832.202
30000 5.839947 0.006351270 919.4935 0 339129.5 339137.8
12 5.802771 0.4444749 14.19697 1.97e-10 134.73313 135.70294
Weibull 250 5.836036 0.07109874 82.34210 0 2829.636 2836.679
30000 5.838373 0.006497584 898.5631 0 339128.8 339145.4
12 5.1744 0.5202828 10.93681 1.83e-06 135.41144 136.38125
loglogistic 250 5.377179 0.08237585 65.53340 0 2849.124 2856.167
30000 5.378736 0.007526099 714.6950 0 341475.9 341492.5
12 5.092055 0.5395235 10.54511 7.03e-06 135.38614 136.35596
lognormal 250 5.291689 0.08875915 59.95347 0 2862.027 2869.070
30000 5.293383 0.008122511 651.7205 0 343138.6 343155.3
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4.2.2 Simulation of Weibull Survival Data without Covariate
We simulated small sample (n = 20) 1000 times, medium samples (n = 1000) 500
times and large samples (n = 200000) 50 times cohort where the time to censoring
of an event is assumed to follow a Weibull distribution. The averages of the fitted
methods for each of the samples of the test statistic, p-values, AIC and BIC are
calculated and are summarized in Table 2. From table 2, we could see that the
semi-parametric tend to perform well than all the parametric model for small and
medium sample by comparing the results of the average AIC and average BIC values
( AIC and BIC). Also since the underlying survival distribution follows the Weibull
distribution, the Weibull distribution outperforms all the parametric distribution in
terms of ( AIC and BIC). However, when the sample is “extremely large” the
semi-parametric model performs poorly among all the methods whiles the Weibull
distribution outperforms all the methods being studied when the sample is “extremely
large”.
4.2.3 Simulation of log-logistic Survival Data with Covariate
Again,samples of 15, 250 and 55000 patients for small, medium and large cohort
respectively were produce. Each of the small samples, medium samples, and large
samples were generated 1000 times, 500 times, and 50 times respectively. The aver-
ages of the intercepts, standard errors, test statistics (z-value), p-values, AICs, and
BICs were calculated for all the iterated generated data. The time to censoring of
an event is assumed to follow log-logistic survival distribution. The details of the
results of the fitted methods for each of the samples are also summarized in Table 3.
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Table 2: Simulation of Weibull Survival data (time to censorship follows Weibull
without covariate)
Model sample(n) intercept Std.Error z p AIC BIC
20 N/A N/A N/A N/A 73.1845 73.1845
Cox 1000 N/A N/A N/A N/A 10009.63 10009.63
200000 N/A N/A N/A N/A 3760872 3760872
20 5.930245 0.2458455 24.14801 5.15e-86 232.444 233.4396
Exponential 1000 5.960220 0.03466166 171.95806 0 11589.67 11594.57
200000 5.964046 0.002452332 2431.990 0 2315973 2315984
20 5.815542 0.3483787 17.53748 1.70e-19 229.9415 231.933
Weibull 1000 5.832879 0.05023059 116.21886 0 11389.67 11399.48
200000 5.837833 0.003550825 1644.086 0 2275994 2276014
20 5.172823 0.4064085 13.50898 5.99e-11 231.06151 233.05297
loglogistic 1000 5.188445 0.05859378 88.64547 0 11456.01 11465.83
200000 5.193596 0.004141231 1254.127 0 2289114 2289134
20 5.077692 0.4281959 12.75151 4.35e-09 231.40035 233.39181
lognormal 1000 5.075810 0.06358719 79.94075 0 11512.79 11522.61
200000 5.081902 0.004497175 1130.031 0 2300710 2300730
The result indicates that the semi-parametric performs well than all the parametric
model for small and medium samples when their average AIC’s and average BIC’s are
compared. Again, the underlying survival distribution follows the log-logistic distri-
bution and so performs well than all the parametric distribution given their AIC and
BIC values. But, for large samples, the semi-parametric tends to perform poorly.
Finally, for large samples, the performance favors the model which underling data
were generated which is the log-logistic model.
4.2.4 Simulation of log-normal Survival Data without Covariate
We simulate series of different samples of 21, 850 and 90877 patients for small,
medium and large cohort respectively where the underling survival is assumed to
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Table 3: Simulation of log-logistic Survival data (time to censorship follows log-logistic
without covariate)
Model sample(n) intercept Std.Error z p AIC BIC
15 N/A N/A N/A N/A 41.15444 41.15444
Cox 250 N/A N/A N/A N/A 1684.184 1684.184
55000 N/A N/A N/A N/A 809659.1 809659.1
15 6.386107 0.3026980 21.18674 8.77e-64 165.66675 166.37480
Exponential 250 6.421266 0.07352000 87.35931 0 2750.116 2753.638
55000 6.422400 0.004953705 1296.485 0 604946.5 604955.4
15 6.374691 0.3081751 22.18989 7.14e-20 166.42417 167.84027
Weibull 250 6.399375 0.08097077 79.25752 0 2748.371 2755.414
55000 6.399589 0.005482754 1167.233 0 604276.2 604294.1
15 5.853048 0.3270505 19.15606 1.23e-16 165.65946 167.07556
loglogistic 250 5.838385 0.08242404 71.06992 0 2726.360 2733.403
55000 5.836116 0.005565791 1048.582 0 599314.4 599332.2
15 5.850588 0.3328321 18.89259 3.95e-15 165.53615 166.95225
lognormal 250 5.833797 0.08570682 68.32991 0 2730.259 2737.302
55000 5.831562 0.005794916 1006.337 0 600256.9 600274.8
follow log-normal distribution. Each samples were simulated 1000 times, 500 times,
and 50 times for small, medium, and large samples respectively. Each generated
set of sample is fitted for all the models and the averages of the results calculated.
The result of the fitted models for each methods in Table 4 indicates that the semi-
parametric again performs well than all the parametric model for small and medium
sample when their AIC ′s and BIC ′s are considered. Also, the underlying survival
distribution follows the log-normal distribution and so performs well than all the para-
metric distribution for small and medium samples given their AIC and BIC values.
However, for large samples, the semi-parametric tends to perform poorly. Finally, for
large samples, the performance favors the model which underling data were generated
which is the log-normal model.
54
Table 4: Simulation of log-normal Survival data (time to censorship follows log-normal
without covariate)
Model sample(n) intercept Std.Error z p AIC BIC
21 N/A N/A N/A N/A 70.62906 79.09117
Cox 850 N/A N/A N/A N/A 8523.776 8523.776
90877 N/A N/A N/A N/A 1651919 1651919
21 6.105117 0.2345773 26.05894 3.07e-114 209.43587 262.47595
Exponential 850 6.118625 0.03675770 166.4634 0 10540.540 10545.285
90877 6.116722 0.003552734 1721.695 0 1127680 1127689
21 6.162951 0.1513406 42.38768 4.91e-93 205.25894 258.87848
Weibull 850 6.182724 0.02547889 242.9230 0 10361.740 10371.230
90877 6.181315 0.002470627 2501.947 0 1108648 1108667
21 5.833951 0.1552328 38.89667 1.05e-108 205.48083 257.33907
loglogistic 850 5.836889 0.02505478 233.1387 0 10264.828 10274.318
90877 5.835077 0.002423438 2407.788 0 1098103 1098122
21 5.833981 0.1547295 38.91167 9.25e-112 206.75782 256.92217
lognormal 850 5.837679 0.02508462 232.8850 0 10251.694 10261.184
90877 5.835743 0.002427653 2403.881 0 1096746 1096765
4.2.5 Simulation of Cox Survival Data without Covariate
Simulations of a series of different samples of 10, 150 and 100000 patients for
small, medium and large cohort respectively where the underling survival is assumed
to follow Cox model. Patient were followed up for 360 days for each sample and
35% of the sample were censored for each sample generated. The iteration for each
sample size is similar to what was described in the previous simulations. Table 5
of the fitted results indicates that the semi-parametric again performs well than all
the parametric model for small and medium sample when their AIC ′ and BIC ′s are
considered. Even for large samples where the underlying generated survival follows
Cox distribution, the Cox still performs poorly with very high AIC and BIC values
for all the models. Thus for large samples the performance tend to favor parametric
models.
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Table 5: Simulation of Cox survival data (time to censorship follows Cox without
covariate)
Model sample(n) intercept Std.Error z p AIC BIC
10 N/A N/A N/A N/A 19.85896 19.85896
Cox 150 N/A N/A N/A N/A 794.7005 794.7005
100000 N/A N/A N/A N/A 383901.1 383901.1
10 5.634211 0.4031290 14.14542 6.6e-19 87.10755 97.31362
Exponential 150 5.621197 0.10140854 55.46912 0.0e+00 1292.8059 1303.0120
100000 1.563474 0.001098 398.5763 0 239613.0 239612.4
10 5.528904 0.2701993 42.56078 6.2e-06 83.66731 104.07946
Weibull 150 5.535819 0.06577372 107.09468 1.03e-183 1247.0264 1267.4385
100000 1.543658 0.0007478 686.0517 0 232677.2 232676.1
10 5.268704 0.3302799 34.37519 8.2e-06 84.60531 105.01745
log-logistic 150 5.296869 0.08276830 83.36597 2.07e-82 1265.7037 1286.1159
100000 1.474360 0.000967 511.0536 0 236523.1 236522.0
10 5.219795 0.3583867 31.58276 1.1e-05 84.76526 105.17741
log-normal 150 5.240754 0.09919346 65.60072 4.62e-80 1283.1576 1303.5698
100000 1.452852 0.001088 437.9845 0 237919.4 237918.2
4.2.6 Simulated Data with Covariate
In the study of survival of clinical data, almost in all cases, certain factors (covari-
ate) contribute to the survival of patients. Thus, in this simulation study, we include
two covariates and compare the performance of the methods under consideration. For
illustration purpose, we simulate one continuous covariate (say age of the patient, X2)
and a binary covariate (say treatments, X1: 0 for those receiving placebo, and 1 for
those in control treatment). The binary covariate could even be gender (male and fe-
male) depending on the researcher’s interest of covariate. Throughout the simulation,
X2 is a continuous covariate and X1 is a binary covariate.
Also, for the case of the binary covariate, we simulate that equal number of patients
must be in each group in all cases. For clarity, we simulate that 50% of the patient
must be in group 0 and the remaining 50% in group 1 of the binary covariate.
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Finally, distribution of covariate generated are as follows. The continuous covari-
ate X1 is generated from a uniform distribution as X1 ∼ Unif(0.7, 1.3). The binary
covariate X1 is generated from Bernoulli distribution as X1 ∼ Bern(0.5).
4.2.7 Simulation of Exponential Survival Data with Covariate
We generate samples of 10, 250 and 45000 for small, medium and large samples
respectively under an exponential distribution. The cohort were followed up for 360
days, 360 days and 150 days for small, medium and large samples. The small samples,
medium samples, and large samples were generated 1000 times, 500 times, and 50
times respectively for each of the sample type. Each of the generated samples were
each fitted for all the methods in this study and the averages of the results summarized
in Table 6. It can be observed that for small and medium samples, performance
favors the semi-parametric model (small AIC and BIC values). For large samples
the performance of the semi-parametric model is poor (high AIC and BIC values )
among all the models.
We mush emphasis that since the samples were generated in a known distribution,
it is obvious that it parameter estimates and performance will be better than other
fully parametric models. In other words, one could simply fit the simulated samples
with the semi-parametric and only one parametric (i.e, the parametric model under
which the samples were simulated)and compare performance. Hence, it is more useful
to compare the performance of parametric distribution model under which samples
were generated with the performance of the semi-parametric model.
Thus, to avoid monotonous in our interpretation, much of the comparative analysis
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will be made between the semi-parametric model and the parametric model which
samples were generated in the rest of the analysis.
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V alue Std.Error z p AIC BIC
10 X1 0.059388 37.665206 0.01258957 0.01811496 0.938753 0.959934
X2 0.0080765 0.1169624 0.002991014 0.01701126
C
ox
250 X1 0.3925214 0.1575598 2.484398 0.07177409 1640.220 1647.263
X2 0.0254968 0.4516806 0.05670527 0.4973323
45000 X1 0.401465 0.01506086 26.65516 3.451791e-132 376161.2 376178.6
X2 0.006848 0.04294151 0.1593177 0.4334652
b0 0.237375 15.541808 0.06759053 0.007452858
10 X1 -0.042988 15.460610 -0.01993349 0.01400709 3.221776 3.253548
X2 -0.0151809 0.1170535 -0.003926755 0.01618880








250 X1 -0.39376 0.1570137 -2.502219 0.07070395 2196.986 2207.550
X2 -0.026629 0.4512109 -0.05945475 0.4972441
b0 5.83984 0.04443916 131.4124 0
45000 X1 -0.40168 0.01505380 -26.68209 1.902403e-132 238525.6 238551.7
X2 -0.0068767 0.04294144 -0.1599885 0.4333185
b0 0.248799 16.263680 0.06409116 0.008345858
10 X1 -0.043485 16.156253 -0.01936511 0.01497723 3.218572 3.260934
X2 -0.0255928 0.1500695 -0.002946753 0.01605309






250 X1 -0.3936983 0.1582113 -2.484287 0.07106828 2197.981 2212.067
X2 -0.0268666 0.4519497 -0.05861969 0.4964511
b0 5.842988 0.04508371 129.6077 0
45000 X1 -0.40278 0.01529061 -26.34092 1.294019e-129 238526.4 238561.2
X2 -0.0069368 0.04308059 -0.1596136 0.4334480
b0 0.236438 8.207400 0.05927121 0.008422555
10 X1 -0.039033 8.092092 -0.01681612 0.01449137 3.225656 3.268018
X2 -0.041383 0.1621016 -0.009605188 0.01505491








250 X1 -0.419574 0.1818082 -2.311889 0.09050745 2203.030 2217.116
X2 -0.0157177 0.5245480 -0.03107060 0.5165724
b0 5.550196 0.04945685 112.2262 0
45000 X1 -0.434446 0.01667724 -26.05034 2.176905e-125 238650.9 238685.7
X2 -0.007031 0.04761656 -0.1463851 0.4368622
b0 0.228019 2.485063 0.05798123 0.008495297
10 X1 -0.036658 2.370384 -0.01663126 0.01414176 3.223758 3.266120
X2 -0.0376628 0.1631550 -0.008718365 0.01499554







250 X1 -0.44644 0.1991860 -2.246301 0.10534848 2214.172 2228.258
X2 -0.0062 0.5745877 -0.01673131 0.5134795
b0 5.67346 0.05633588 100.7119 0
45000 X1 -0.47334 0.01890206 -25.04305 5.451927e-117 239658.7 239693.5
X2 -0.0091616 0.05415234 -0.1677195 0.4336860
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4.2.8 Simulation of Weibull Survival Data with Covariate
We simulate samples of 10, 1000 and 200000 for small, medium and samples under
the distribution model. The cohorts of each samples were follow up for a period of 360
days and each sample type simulated 1000 times, 500 times and 50 times for small,
medium, and large sample respectively. The simulated samples were each fitted for
each model and the averages of the results are summarized in Table 7. Comparing
the AIC and BIC values, the semi-parametric model tend to perform well for small
and medium samples. However, for very large samples, the semi-parametric model
performs poorly among all the models since it has both high AIC and BIC values.
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V alue Std.Error z p AIC BIC
10 X1 0.0396 50.178426 0.03332747 0.04536250 2.509183 2.566675
X2 0.045357 0.3101453 0.006956623 0.04482158
C
ox
1000 X1 0.273027 0.07792900 3.501730 0.01189620 8508.132 8517.947
X2 0.014356 0.2243463 0.06390703 0.5035667
200000 X1 0.279118 0.005507000 50.68400 0 3106802 3106822
X2 0.00411 0.01583917 0.2595638 0.5237324
b0 0.599343 0.3055827 0.1896213 0.01936460
10 X1 -0.02581 14.583251 -0.04890304 0.04025647 8.579595 8.66583
X2 -0.060689 0.2994519 -0.012230750 0.03794964 2








1000 X1 -0.305745 0.07784194 -3.926465 0.00792505 8746.762 8761.485
X2 -0.016651 0.2243627 -0.07414446 0.4674620
b0 5.742962 0.01634429 351.3747 0
200000 X1 -0.3120770 0.005501265 -56.72800 0 1746638 1746668
X2 -0.004469 0.01583951 -0.2822335 0.4858628
b0 0.611206 0.3871473 0.1763026 0.02207182
10 X1 -0.011929 28.856142 -0.04461817 0.04174504 8.600580 8.715562
X2 -0.062399 0.3783291 -0.011493813 0.04117687






1000 X1 -0.391027 0.11175300 -3.494777 0.01180615 8620.648 8640.279
X2 -0.020958 0.3209838 -0.06463003 0.5029684
b0 5.842158 0.02341978 249.4558 0
200000 X1 -0.399644 0.007903925 -50.56274 0 1721117 1721158
X2 -0.005882 0.02267720 -0.2595496 0.5237207
b0 0.565613 0.4027479 0.1602734 0.02374943
10 X1 -0.017981 23.960318 -0.04111905 0.03892699 8.613693 8.728675
X2 -0.072547 0.3951261 -0.014286017 0.04167630








1000 X1 -0.423621 0.12919552 -3.276892 0.01768908 8638.123 8657.754
X2 -0.014541 0.3727170 -0.03873524 0.5104250
b0 5.27796 0.02716112 194.3222 0
200000 X1 -0.4317097 0.009138496 -47.24100 0 1724586 1724627
X2 -0.008002 0.02635224 -0.3040300 0.5273711
b0 0.555313 0.4130427 0.1579265 0.02375455
10 X1 -0.038287 7.397695 -0.04029724 0.03865069 8.600742 8.715724
X2 -0.060386 0.4037084 -0.013968284 0.04025346







1000 X1 -0.423621 0.12919552 -3.276892 0.01768908 8684.567 8704.198
X2 -0.014541 0.3727170 -0.03873524 0.5104250
b0 5.260330 0.02999507 175.3755 0
200000 X1 -0.458007 0.010084970 -45.41519 0 1733950 1733991
X2 -0.009537 0.02907691 -0.3288029 0.4965488
61
4.2.9 Simulation of log-logistic Survival Data with Covariate
We simulates a series of different samples of 20, 550 and 20000 patients for small,
medium and large cohort respectively where the underling survival is assumed to
follow log-logistic distribution. Each generated set of samples were generated 1000
times, 500 times, and 50 times for small, medium, and large samples respectively and
was fitted for all the models. The averages of the fitted samples for each model is
also summarize in Table 8. For small and medium samples, the results of the semi-
parametric and parametric log-logistic model are similar in terms of their average
p-value (p− value) (none of the covariate were significant at 5% level of significant).
However, the semi-parametric provides a better performance for small and medium
samples in terms of their AIC and BIC values. The results also indicates that for very
large samples, covariate X1 is significant for all the method but X2 is not significant
for any of the methods. Thus, the results do not differ in terms of the number of
significant predictors. Also by comparing the values of AIC and BIC values, semi-
parametric tend to perform poorly among all the models for large samples.
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V alue Std.Error z p AIC BIC
20 X1 0.138287 248.19757 0.2614369 0.48917 47.96747 49.95893
X2 0.000368 2.395963 -0.018828988 0.49118
C
ox
550 X1 0.487035 0.1875895 2.585173 0.064878 1474.888 1483.508
X2 0.003297 0.5294499 0.003957619 0.480203
20000 X1 0.405298 0.01981992 20.44806 3.211139e-75 194801.0 194816.8
X2 -0.0112 0.05671206 -0.1982523 0.5222800
b0 5.909656 59.18038 2.373453 0.11475
20 X1 -0.173364 171.72863 -0.3034061 0.43979 112.01460 115.00180
X2 -0.007068 2.422518 0.017113612 0.440556








550 X1 -0.478161 0.1875405 -2.538584 0.0673807 1720.794 1733.723
X2 -0.002751 0.5293852 -0.002925319 0.48600
b0 6.225267 0.05858806 106.25615 0
20000 X1 -0.394317 0.01979715 -19.91698 7.575187e-71 145378.5 145402.2
X2 0.011096 0.05671265 0.1963765 0.5301931
b0 6.814543 94.22768 1.540211 0.24439
20 X1 -0.385897 230.61375 NaN 0.480595 108.72271 112.70564
X2 -0.002161 4.513716 0.016710200 0.48357






550 X1 -0.3645209 0.1437305 -2.517728 0.065862 1711.686 1728.926
X2 -0.001941 0.3974758 -0.004027942 0.48032
b0 6.1396 0.05011332 122.52371 0
20000 X1 -0.34997 0.01702828 -20.54778 4.788047e-76 145057.3 145088.9
X2 0.00973 0.04834651 0.2011205 0.5178028
b0 6.18586 109.86290 1.327063 0.2986678
20 X1 -0.399873 270.53292 -Inf 0.48047 108.58176 112.5646
X2 -0.052902 4.759786 0.009236182 0.480496








550 X1 -0.3834139 0.1498249 -2.548083 0.06448824 1711.415 1728.655
X2 -0.002794 0.4204924 -0.005860332 0.4791404
b0 5.828024 0.05604131 104.00241 0
20000 X1 -0.39766 0.01887624 -21.06410 3.334302e-79 144880.4 144912.0
X2 0.007845 0.05427417 0.1444703 0.5334322
b0 6.211266 46.79530 1.303389 0.3052368
20 X1 -0.419369 91.47112 -0.2903933 0.4780203 108.39740 112.38033
X2 -0.0883192 4.933734 0.002704278 0.4748853







550 X1 -0.424021 0.1677893 -2.524677 0.069854 1714.329 1731.569
X2 -0.002391 0.47693 -0.002978085 0.4756976
b0 5.853185 0.06029883 97.07686 0
20000 X1 -0.414857 0.02027311 -20.46037 1.151491e-73 145176.4 145208.0
X2 0.006618 0.05829062 0.1140256 0.5675334
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4.2.10 Simulation of log-normal Survival Data with Covariate
A simulation study of series of samples of size 21, 850 and 100000 for small,
medium and large respectively was conducted for comparative performance of survival
models method. The time to censoring of the samples were generated under the log-
normal distribution. The follow up time for the sample are 360 days, 360 days and
300 days for small, medium and large samples respectively. the type of sample size
were generated 1000 times, 500 times and 50 times for small, medium and large
samples respectively. For each of the generated sample data, the data is fitted for all
the methods under study and averages of the results calculated and summarized in
Table 9. The results of the semi-parametric is similar to the results of the parametric
simulated log-normal under study in terms of significant number of covariates for each
type of sample size. When performances are compared by using the AIC and BIC
values , the semi-parametric tends to perform better since it has the minimum AIC
and BIC values for small and medium samples.
However, when the samples is very large, the results differ when AIC and BIC
are compared.
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V alue Std.Error z p AIC BIC
21 X1 0.733287 27.742208 1.02725 0.3409219 67.64085 69.7299
X2 0.016421 1.8690216 0.015102 0.4809397
C
ox
850 X1 0.62989 0.089842 7.006612 3.190324e-07 6448.789 6458.280
X2 0.001612 0.2546217 0.005982 0.5200298
100000 X1 0.67117 0.008997392 74.59536 0 1151509.5 1151528.5
X2 0.004558 0.02534807 0.179672 0.5104825
b0 6.4222 30.350625 3.488097 0.014983251
21 X1 -0.61013 29.118089 -0.877467 0.3935501 183.10829 186.2419
X2 -0.027857 1.7999060 -0.020866 0.5385295








850 X1 -0.535069 0.089535 -5.972013 3.554397e-06 7221.937 7236.173
X2 -0.001113 0.2545625 -0.003871 0.5712404
b0 6.407502 0.02628869 243.737 0
100000 X1 -0.585787 0.008977863 -65.2473 0 731677.6 731706.2
X2 -0.004146 0.02534705 -0.163452 0.5560081
b0 6.071413 17.520783 6.82095 0.002879047
21 X1 -0.3795067 16.889717 -1.07762 0.3254981 177.66508 181.8432
X2 -0.007822 0.9228086 -0.01787 0.4549552






850 X1 -0.337235 0.047784 -7.054729 2.794884e-07 7001.219 7020.200
X2 -0.000932 0.1332372 -0.007425 0.5094513
b0 5.995640 0.01307157 458.685 0
100000 X1 -0.3372 0.004556228 -74.0077 0 706861.8 706899.8
X2 -0.002248 0.01252263 -0.17882 0.5010833
b0 5.865219 12.870907 6.246614 0.002946945
21 X1 -0.409601 12.204112 -1.184249 0.3089563 177.01406 181.1922
X2 -0.018099 0.9738970 -0.034531 0.4563818








850 X1 -0.391265 0.05173026 -7.570256 1.898828e-08 6974.019 6993
X2 0.000842 0.1485039 0.0063715 0.5130259
b0 5.82241 0.01437375 405.078 0
100000 X1 -0.384998 0.004872704 -79.01075 0 704699.7 704737.7
X2 -0.003252 0.01388699 -0.233606 0.5018062
b0 5.868668 4.554796 6.1931 0.002754313
21 X1 -0.406912 3.880951 -1.203706 0.3126003 176.70719 180.8853
X2 -0.024051 0.9788660 -0.034284 0.4626586







850 X1 -0.399398 0.05279084 -7.571258 2.040593e-08 6964.787 6983.768
X2 -0.0013 0.15127 -0.00759 0.5172663
b0 5.839931 0.01488516 392.338 0
100000 X1 -0.39963 0.005035024 -79.36992 0 703728.5 703766.5
X2 -0.003867 0.01434987 -0.269091 0.5036786
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4.3 Simulation of Semi-Parametric Results
We use the function sim.survdata which depends on the package coxed to Sim-
ulate duration data for the Cox proportional hazards (semi-parametric) model. A
call to the function is
sim.survdata(N = 1000, T = 100, type = “none”, hazard.fun = NULL, num.data.frames =
1, fixed.hazard = FALSE, knots = 8, spline = TRUE,X = NULL, beta = NULL, xvars =
3,mu = 0, sd = 0.5, covariate = 1, low = 0, high = 1, compare = median, censor =
0.1, censor.cond = FALSE)
The description of the argument is
• N : Number of observations in each generated data frame. Ignored if X is not
NULL.
• T: The latest time point during which an observation may fail. Failures can
occur as early as 1 and as late as T.
• Type: If “non” (the default) data are generated with no time-varying covariates
or coefficients. If “tvc”, data are generated with time-varying covariates, and if
“tvbeta” data are generated with time-varying coefficients (see details).
• hazard.fun: A user-specified R function with one argument, representing time,
that outputs the baseline hazard function. If NULL, a baseline hazard function
is generated using the flexible-hazard method as described in [8] (see details).
• num.data.frames: The number of data frames to be generated.
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• fixed.hazard: If TRUE, the same hazard function is used to generate each data
frame. If FALSE (the default), different drawn hazard functions are used to gen-
erate each data frame. Ignored if hazard.fun is not NULL or if num.data.frames
is 1
• knots: The number of points to draw while using the flexible-hazard method to
generate hazard functions (default is 8). Ignored if hazard.fun is not NULL.
• X: A user-specified data frame containing the covariates that condition duration.
If NULL, covariates are generated from normal distributions with means given
by the mu argument and standard deviations given by the sd argument.
• beta: Either a user-specified vector containing the coefficients that for the linear
part of the duration model, or a user specified matrix with rows equal to T for
pre-specified time-varying coefficients. If NULL, coefficients are generated from
normal distributions with means of 0 and standard deviations of 0.1.
• xvars: The number of covariates to generate. Ignored if X is not NULL.
• mu: If scalar, all covariates are generated to have means equal to this scalar. If
a vector, it specifies the mean of each covariate separately, and it must be equal
in length to xvars. Ignored if X is not NULL.
• sd: If scalar, all covariates are generated to have standard deviations equal to
this scalar. If a vector, it specifies the standard deviation of each covariate
separately, and it must be equal in length to xvars. Ignored if X is not NULL.
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• covariate: Specification of the column number of the covariate in the X matrix
for which to generate a simulated marginal effect (default is 1). The marginal
effect is the difference in expected duration when the covariate is fixed at a high
value and the expected duration when the covariate is fixed at a low value.
• low: The low value of the covariate for which to calculate a marginal effect.
• high: The high value of the covariate for which to calculate a marginal effect.
• compare: The statistic to employ when examining the two new vectors of ex-
pected durations (see details). The default is median.
• censor: The proportion of observations to designate as being right-censored.
• censor.cond Whether to make right-censoring conditional on the covariates (de-
fault is FALSE, but see details)
4.3.1 Simulation of Cox Proportional Hazard Survival Data with Covariate
In the case of the semi-parametric, we generate cohorts of 8, 1000 and 100000 for
small, medium and large sample respectively where the time to censoring follows the
Cox Proportional Hazard model. Each samples were followed up a period of 365 days
with 35% of samples experiencing the event (death). The results of the average of the
fitted models for each sample are also summarize in Table 10. The results of the fitted
models are similar for all the methods in terms of the number of significants covariate
for all the samples. However, for small and medium samples, the semi-parametric
model performs better when the values of the AIC and BIC are compared. But for
large samples, semi-parametric performs poor when the AIC and BIC are compared.
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V alue Std.Error z p AIC BIC
8 X1 0.00391 0.0046236 7.5308e-05 0.000568 0.029451 0.03343407
X2 0.002126 0.002235 0.0016047 0.00094063
C
ox
1000 X1 0.00843 0.039554 0.21936 0.062683 7647.643 7643.643
X2 0.00091 0.039593 0.03236787 0.069607
100000 X1 0.08389 0.003939 21.29 2e-16 1376806 1376825
X2 0.07665 0.003962 19.35 2e-16
b0 0.01399 0.00230828 0.012125 1.3521e-11
8 X1 -0.00291 0.0033780 7.0543e-05 0.00035836 0.14272196 0.14869636
X2 -0.00184 0.00171767 -0.001780 0.00087225







1000 X1 -0.00776 0.039321 -0.197 0.06321495 8541.164 8535.164
X2 0.000794 0.039389 0.0122915 0.06519974
b0 5.63067 0.00392 1436.8 2e-16
100000 X1 -0.04353 0.00392 -11.1 2e-16 863504.1 863532.6
X2 -0.04085 0.00395 -10.3 2e-16
b0 0.01257 0.00096973 0.02646 1.4905e-33
8 X1 -0.00213 0.0012810 -1.2571e-03 0.00029967 0.13486288 0.14282874
X2 -0.000944 0.00082513 -0.0019159 0.0007318






1000 X1 -0.00511 0.026881 -0.21958 0.06853866 8227.314 8219.314
X2 0.00492729 0.026936 -0.00920692 0.06718532
b0 5.57014 0.00265 2102.2 2e-16
100000 X1 -0.03887 0.00264 -14.7 2e-16 852045.5 852083.5
X2 -0.03604 0.00266 -13.6 2e-16
b0 0.01255 0.00096615 0.026977 1.8843e-31
8 X1 -0.00215 0.0013577 -1.4099e-03 0.0002485 0.13670952 0.14467537
X2 -0.00124 0.00084896 -0.002609 0.00041610








1000 X1 -0.00615 0.034836 -0.22063 0.06965971 8359.350 8351.350
X2 0.006799 0.034953 0.00565096 0.07258594
b0 5.37816 0.00338 1591.2 2e-16
100000 X1 -0.04904 0.00337 -14.6 2e-16 870532.3 870570.3
X2 -0.04649 0.00339 -13.7 2e-16
b0 0.012575 0.00101086 0.02546 2.673e-31
8 X1 -0.00203 0.0014379 -9.6347e-04 0.0002094 0.13589413 0.14385999
X2 -0.001357 0.00076809 -0.002886 0.0004698







1000 X1 -0.00694 0.040013 -0.1917 0.068778 8472.269 8464.269
X2 0.004669 0.040158 -0.000221 0.071131
b0 5.29659 0.00468 1132.8 2e-16
100000 X1 -0.06204 0.00455 -13.6 2e-16 888976.6 889014.6




We apply the result in the simulation studies to a real clinical data set. In the
this section, we also provide some steps that could be used to analyze survival clinical
data set. We start the analysis by visualizing the behavior of the data set through
graphical approach using the Kaplan Meier non-parametric approach.
4.4.2 Description of Data Set
The data consist of 136 cervical cancer patients. Patients were followed up for a
period of one year (365 days). The event is patients who died due to cervical cancer
while those who were alive or lost to follow up are considered censored at the time of
collecting the data. The following censoring assumptions on patient were made.
• Patients who were alive disease-free were considered censored.
• Patients who died from other causes than cervical cancer were considered censored.
• Patients who were still alive with disease as at their last follow up date were con-
sidered to be censored.
• Patients who were lost to follow-up were considered to have been censored.
The dependent variable is the time (days) until death of a patient.
The covariates considered in this study are age of the patients and treatments given
to patient. Age is a continues covariate but the treatment is a discrete covariate with
three levels. Patients diagnosed with only teletherapy are considered as group one.
Patients diagnosed with combination of teletherapy and brachytherapy are considered
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as group two. Patients diagnosed with combinations of teletherapy, brachytherapy
and chemotherapy were considered as group three. The categorical covariate (treat-
ment) were coded using i-1 dummy variables to avoid over parametrization as follows.
xi−1 =

1 if patient is in group i, for i = 1, 2,3
0 otherwise
In this study, treatment group 3 was used as the baseline for the treatment covariate.
The table below shows a summary of the first four cases.
Table 11: First four cases for each treatments group
follow up time (days) event age treatment 1 treatment 2
189 0 45 1 0
148 1 66 1 0
100 0 52 1 0
221 0 67 1 0
Event: 1 = if patient died, 0 = if patient alive (censored)
4.5 Preliminary Results
The cancer patients were diagnosed with three kinds of treatments at age 27 years
and older. The mean age of the sample is 59.45588 years with standard deviation
14.38202 years and ages rage from 27 years (minimum age) and 93 years (maximum
age) at the beginning of the study.
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Table 12: Descriptive Statistics of Samples
Age (years) patients who died patients who survived Total
mean 70.625 58.75781 59.45588
standard deviation 14.12129 14.16091 14.38202
range 50 - 90 27 93 27 - 93
total (n) 8 128 136
4.6 Kaplan Meier Estimate
First, we analyze the data by looking at the trend of the survival of patient using
Kaplan Meier (K-M) estimate. Figure 3 shows K-M graph that provides a general
survival curve of patients. The graph is a step function that decreases monotonically
(changes) at any time a patient experience the event (death). The graph gives the
probability that a patient will survive at any given time (day). For instance, the
probability that a patient will survive till day 300 is estimated to be 0.9 (from the
graph). The estimated K-M survival probability at the end of the year (365 days) is
about 0.85 from the graph. The graph also indicates that there were some censored
observations (patient still alive at the end of 365 days) since the graph does not goes
zero. Figure 4 provides the graph of the hazard of patients. It can be observe that
the hazard of a patient increase as the days increase.
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Figure 3: Kaplan Meier Graph for no covariate
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Figure 4: Kaplan-Meier Hazard Estimates
4.7 Comparing Survival Models
We fit a survival models to the data set for both semi-parametric model under
the Cox Proportional Hazard Model (CPHM) assumption and the parametric sur-
vival model under the Accelerated Failure Time Model (AFTM). We compare the
best model fit using the AIC and BIC. The results is summarized in Table 13. The
result of the fitted model indicates that the semi-parametric model is a good fit since
it has the smallest AIC (68.45273) and BIC(77.1907) values. Among the parametric
case, exponential survival model is indicated a better fit under the AFTM. We should
note that the CPHM is accurate and can be used for any inferences and prediction
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provided the mild assumptions (assumption of proportionality hazard) is fully satis-
fied. Since the CPHM has been selected a better fit among all the model comparison,
we now provide some steps to model and explain survival clinical data using the
semi-parametric method. We start this by checking the selected model assumption.







Table 14: Summary of semi-parametric model
covariate coefficient exp(coef) se(coef) z Pr(> |z|) lower .95 upper .95
age 0.05962 1.06143 0.02720 2.192 0.0284 1.0063 1.120
treatment 1 0.44668 1.56311 0.92302 0.484 0.6284 0.2560 9.543
treatment 2 0.03533 1.03596 0.82639 0.043 0.9659 0.2051 5.233
4.8 Some Steps to Model and Explain Survival Clinical Data
The first step to model and explain survival clinical data under the semi-parametric
model is to check model assumptions through model diagnostic.
4.8.1 Model Diagnostic/Adequacy
We assess the validity of the model to the data via Goodness-of-good fit. The
diagnostic check is based on the residuals of the selected fitted model. Three kinds
of model adequacy will be checked: assumptions of proportional hazard, influen-
tial/outlier observation and nonlinearity relationship between the log hazard and the
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covariates.
4.8.2 Assessing Proportional Hazard (PH) Assumption
Two approaches will be used. First is the statistical approach (hypothesis testing)
which tests the null hypothesis that proportional hazard assumption is met. This ap-
proach is done by estimating the test of the proportional hazards assumption for each
of the covariate by correlation between the corresponding set of Schoenfeld’s residuals
and survival time. Table 15 provides the results for the test. The values for the Rho
shows the Pearson product moment correlation between the Schoenfeld’s residuals
and lagged residuals for each covariate. The Chisq values are the test statistics. The
“Global” gives the global test of probability for the model at once. The p-values
give probability values under which the null hypothesis is tested. From the table,
the p-values for each of the covariate suggests that PH assumption is met at α = 5%
significant level. Also the global test is also not statistically significant. Therefore,
we can assume that proportional hazard is met.
Table 15: Test for Proportional Hazard Assumption
rho chisq p
age 0.281 0.564 0.453
teletherapy -0.183 0.231 0.631
telebrachy -0.229 0.435 0.510
GLOBAL NA 1.123 0.772
In Figure 5, we provide a graphical approach to check assumption of PH based on
the Schoenfeld residual. The Schoenfeld residual are independent of time. A plot
for each of the covariate that shows random pattern against time is evidence that
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PH assumption is met. The solid line is a smoothing spline fit to the plot, with the
dashed lines representing a ± 2-standard-error band around the fit. A systematic
departures from a horizontal line shows non-proportional hazards, since proportional
hazards assumes that estimates of the covariates do not vary much over time. From
the graphical inspection, each of the plotted shoes a random scatter along with cor-
responding p-values for each covariate indicating that PH appears to be valid. Also,
each p-value is not significant at 5% significant level showing that PH assumption
is met. Finally, the p-value of the Global Schoenfeld test is 0.7715 indicating that
overall, the PH assumption is reasonably satisfied.
Figure 5: Schoenfeld residuals for covariate against time.
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4.8.3 Checking Influential/Outlier Observation
Figure 6 shows a graphical display to check any influential/outlier observation.
Influential observation is check by comparing he magnitude of the largest dfbeta val-
ues in the plotted graphs to each of the corresponding Cox regression coefficient. Any
largest in magnitude of dfbeta value greater than regression coefficient indicates in-
fluential observation. From the graph below, comparing the magnitude of the largest
dfbeta value to each of the corresponding regression coefficient indicates that none of
the observation in influential.
Figure 6: Index plots of dfbeta for Cox regression of time to age and treatment.
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4.8.4 Checking the Assumption of Nonlinearity
One assumption of the semi-parametric Cox model is the linearity of the covariate.
The assumption of the nonlinearity only holds for continuous covariate. Since age
is the only continuous covariate, we check for nonlinearity of its functional form.
An easy way of checking this is by plotting the Martingale residuals against the
continuous covariate. Any systematic pattern in the plot suggests that covariate is not
fitted adequately and the assumption is violated. From figure 7, the is no systematic
pattern in the plot of the graphs indicating that the assumption of nonlinearity of
the continuous covariate age is moderately met.
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Figure 7: Nonlinearity of functional form of covariate age
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4.8.5 Checking Overall Model Fit
We check the overall model fit using the Cox-Snell residuals. We plot the log
cumulative hazard of Cox-Snell residual along with the best fitted straight line. If
the straight line graph coincide with the step functions then the model is well fitted
can be used for further analysis such as predictions and inferences. From figure 8,
we can observe that both the straight and the step function graph reasonably move
along together indicating that over all the model is well fitted.
Figure 8: Cumulative hazard plot of the Cox-Snell residual for Cox PH model to
check the overall fitted model.
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4.9 Estimating the Semi-Parametric Model
Since the assumption of the selected model is fully satisfied through diagnostic
check, the next step is to estimate the model and observe significant covariates and rel-
evant inferences. Table 16 below provides the summary of fitted model with detailed
explanation of the output as follows: The coefficient column provides the estimate
of the coefficient of the regression parameters(Xage, Xtreatments) with interpretation
that the estimated coefficient b1, gives the expected change of the log hazard ratio for
every one unit increase in the corresponding covariate (X1) when all other covariate
are held constant (or are equal to zero). For instance, the estimated coefficient for age
is 0.05962 indicating the expected change of the log hazard ratio for every one unit
increase in age when treatment is held constant (when treatment is zero). Also, the
sign of the positive coefficient indicates a positive relationship between the covariate
and the event (death). For instance, the positive coefficient of age indicates that the
older (higher) the patient the higher the risk of patient dieing with cancer.
The exp(coef)gives the hazard ratio (HR) between two groups with HR < 1 in-
dicating reduction in hazard (good prognostic factor in cancer studies), HR > 1
indicating increase in hazard (bad prognostic factor in cancer studies) and HR = 1 in-
dicating no effect. Three groups of treatment were considered in this studies with pa-
tient receiving teletherapy as treatment 1, combination of teletherapy and chemother-
apy as treatment 2 and combinations of teletherapy+chemotherapy + brachytherapy
as treatment 3. Treatment 3 was used as the baseline to comparethe other two
treatments. From the table below, for teletherapy we have exp(0.44668)=1.56311
indicating that patients receiving teletherapy only increase hazard by a factor of
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1.56311(56.31 %) times higher than patients receiving treatment 3 when age is held
constant. Also, for age we have exp(0.05962)=1.06143 indicating that a unit increase
in age increase hazard (death) by a factor of 1.06143 (6.1%) when treatment is held
constant (bad prognostic in this case).
The se(coef) column gives the standard error of the estimated coefficient.
The z column gives the value of the Wald statistic which is calculated as the ratio




statistic test under the null hypothesis if the regression parameter is zero (β = 0).




at α = 5% significant








). From the table,
only age is statistically significant implying that age is the only factor in this study
that contribute to the hazard of cancer patient.
The Pr(> |z|) gives the corresponding p-value of the Wald statistic for large
samples. It measure the statistical significant of the covariate. It gives the same
conclusion as the Wald statistic. Any Pr(> |z|) less than the α − level(5%) of
significant indicate as statistically significant different from 0. From the table, none
of the treatments is statistically significant (p-value > 0.05) but age is statically
significant (p-value = 0.0284).
The lower 0.95 and upper 0.95 give the confidence interval of the hazard ration
(exp(coef)). It also measure the statistical significant of the covariate. It also gives
the same conclusion as the result of the Wald test and p-value approach. To measure
the importance of the covariate, any covariate which confidence interval include one
implies that the covariate is not statistically significant. From the table below, age
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has a confidence interval of 1.0063 and 1.120 which does not include one. Hence age is
statistically significant. But treatment has confident interval including one indicating
none significant factor.







The above three separate models can be put into a single model as:
λ(t)death = λ(t)alivee
0.05962Xage+0.44668Xteletherapy+0.03533Xtele−brachy (55)
Table 16: Summary of semi-parametric model
covariate coefficient exp(coef) se(coef) z Pr(> |z|) lower .95 upper .95
age 0.05962 1.06143 0.02720 2.192 0.0284 1.0063 1.120
teletherapy 0.44668 1.56311 0.92302 0.484 0.6284 0.2560 9.543
tele-brachyterapy 0.03533 1.03596 0.82639 0.043 0.9659 0.2051 5.233
4.10 Further Analysis of Model Development
As in the case of statistical model, health analyst may want to fit model that
involves only significant covariate by fitting each covariate separately (similar to step-
wise regression). Table 17 shows the result of the fitted Cox model involving only
treatment only. We can observe that gain none of the treatments has a significant
influence (p-values > 0.05) on the hazard of cancer patient under study as in the case
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of the fitted full model in Table 16. However, the sign of the coefficient of treatment
II (teletherapy + brachyterapy) changes to negative. However, in Table 18 which
provides a summary of fitted Cox model involving only covariate age shows signifi-
cant (p-value = 0.0297) factor with a positive coefficient sign. This shows age is a
key contributing covariate that significantly affect the hazard of the cervical cancer
patient. Since age was only significant factor (in this stepwise approach) the inter-
pretation of the coefficient is similar to those in fully fitted model discussed above.
We provide write the model as:
λ(t)death = λ(t)alivee
0.05785Xage (56)
Table 17: Summary of fitted semi-parametric model involving treatment only
covariate coefficient exp(coef) se(coef) z Pr(> |z|) lower .95 upper .95
teletherapy 0.24236 1.27425 0.91587 0.265 0.791 0.2117 7.671
tele-brachyterapy -0.05566 0.94586 0.82324 -0.068 0.946 0.1884 4.749
Table 18: Summary of fitted semi-parametric model involving age only
covariate coefficient exp(coef) se(coef) z Pr(> |z|) lower .95 upper .95
age 0.05785 1.05955 0.02661 2.174 0.0297 1.006 1.116
Finally, differences in risk factor of age group are influence by some external factors
such as regular exercise, diet, frequent medical check up, race and so forth making age
at which patient is at a higher risk of cancer differ from geographical setting to the
other. For instance, whiles age groups of patient above thirty years may be at higher
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risk of cervical cancer in Asia, the result of the age group may be different in USA due
to the some factors listed above. Thus, we or any health analyst may be interested
to know which of the age category from this data (geographical setting) has a higher
risk of dieing with the cancer under study. We investigate this by categorizing age
into two groups. We compare patients over 64 years and those patient of 64 years
and below (age ≤ 64 years) where patients below 65 years are use as the baseline.
Table 20 shows the assumption of the newly fitted model where the assumptions of
the proportional hazard is fully met. The assumption of linearity is omitted since the
two covariate are now categorical. Table 19 provides a result of the fitted Cox model
for the two categorical covariate. Again, none of the treatment is significant (p-value
> 0.05). Age of the patient is significant (p-value = 0.0385) with patients over 65
years more at a higher risk of dieing with the cancer (base on positive coefficient
value) than those patient below 65 years. That is patients over 65 years old are at a
higher risk of dieing with the cancer by a factor of 5.4592 (45.9%) times higher than
patients less than or equal to 65 years when treatment is held constant. The fully
fitted model in this case is written in a single model as:
λ(t)death = λ(t)alivee
1.6973Xage>65yrs+0.2668Xteletherapy−0.1966Xtele−brachy (57)
Table 19: Summary of fully semi-parametric model for two categorical covariate
covariate coefficient exp(coef) se(coef) z Pr(> |z|) lower .95 upper .95
age > 65 years 1.6973 5.4592 0.8194 2.071 0.0383 1.0955 27.205
teletherapy 0.2668 1.3057 0.9146 0.292 0.7705 0.2175 7.840
tele-brachyterapy -0.1966 0.8215 0.8328 -0.236 0.8133 0.1606 4.202
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Table 20: Test for Proportional Hazard Assumption for two covariate
rho chisq p
age > 65 years 0.0301 0.00672 0.935
teletherapy -0.2418 0.43035 0.512
telebrachy -0.2713 0.59551 0.440
GLOBAL NA 0.72411 0.868
Again, if we are interested in only the covariate (age category) that has a major
significant effect on the hazard of patient then Table 21 provides the results in this
case. The interpretation of the coefficient and other important results is similar to
those explain earlier. The fitted model is written as:
λ(t)death = λ(t)alivee
1.6695Xage>65yrs (58)
Table 21: Summary of semi-parametric model for categorical age
covariate coefficient exp(coef) se(coef) z Pr(> |z|) lower .95 upper .95
age > 65 years 1.6695 5.3093 0.8169 2.044 0.041 1.071 26.33
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5 DISCUSSION AND CONCLUSION
Simulation studies are mostly used to demonstrate, justify and evaluate properties
of statistical method when theoretical properties ar difficult to handle. They are
also useful for assessing the behavior of analytic techniques when various conditions
impose difficulties in practice. One main benefit of this technique is that when the
properties are well characterized, they can be used with high amount of confidence.
One main purpose of this study is to propose a best way of analyzing survival clinical
data which results can be estimated and trusted with confidence. One of the main
challenges of health analyst in the study of survival analysis is which method to be
used to analyze their data. We have demonstrated how the semi-parametric survival
model tends to be robust and how suitable it can approximate the parametric survival
model in the study of health data using R - package proposed by [19]. We simulated
a right censored clinical data that follows various forms of parametric distributions
and semi-parametric distribution. The simulation study was conducted taken into
consideration the various forms of sample sizes. We considered three forms of sample
sizes: small samples (n < 30), mild sample (30 ≤ n ≤ 5000) and large samples (n
>5000). From the study, when the sample size of the simulation study is small or
mild, the semi-parametric model tends to perform well than the parametric model
based on model comparison techniques. However, for large samples, the parametric
method outperforms the semi-parametric model.
To assess the effectiveness of our proposed technique, we compared the reliability
and effectiveness of the proposed technique using a real clinical data of mild samples.
Based on the results of various model comparison, the semi-parametric under the
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Cox Proportional Hazard emerged best fit conforming to the results of the simulation
study supported with concise steps to model and explain survival clinical data.
In practice, researchers in the study of survival clinical studies (cancer studies
for instance) do not have control over the samples to be sued to test the efficacy of
certain treatments as in the case of survival analysis in the application of business
and so sample size is mostly small or mild. For instance, a health analyst can not
go around and be choosing kidney cancer patients randomly to be in his/her study
to test efficacy of certain treatments. Only the few patients who truly have kidney
cancer and avail themselves to be treated are used to test treatment efficacy. Thus,
in most of survival analysis of cancer study, the sample size is either small or mild
making this proposed study efficient.
Nevertheless, we believe that it may not always be the case in the study of sur-
vival clinical data that the semi-parametric will outperform the parametric model
even for small and mild clinical data especially when the assumptions of the para-
metric model underlying the data is well satisfied. When the assumptions of the
parametric methods fits the data well, the results of the estimates are always better
and reliable than the semi-parametric model. Thus, even when clinical data satisfied
both the semi-parametric and parametric model, we recommend that semi-parametric
approach may be used due to its flexibility, simplicity and availability in many soft-
ware and the two results may be approximated unless the researcher is an expect in
handling parametric techniques.
We hope that the proposed techniques will allows researchers to relax extreme
parametric assumptions on the survival model imposed by existing methods. Thus,
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unless one is more convinced and confidence of the kind of parametric model that fits
well of the survival clinical data, we propose that the semi-parametric model must be
used.
5.1 Future Work
We proposed a moderate efficient method for analyzing survival clinical data
through simulation studies with a more reliable steps by steps approach to model
and explain survival clinical data. However, more can be done to validate the results
of this study. For instance, to compare the reliability of our proposed methods us-
ing real clinical data, certain covariate such as time varying covariate (covariate that
changes over time during follow up periods) such as smoking status, income and so
forth and other time independent covariate (covariate that do not change over the
study period) such as family history for large and small samples of real clinical data
were not used to compare the results of the simulation study. We recommend that
future studies that compare the reliability of our propose method be conducted to
include more covariates that are time dependent and independent be used for each
of small samples and large samples. Furthermore, the research could be extended to
situation where subjects experience multiple events of interest.
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mat[i,6]<-AIC(cox.model.nocov.w.s,k = log(length(start )))
mat[i,12]<-AIC(weib.model.nocov.w.s,k = log(length(start )))
mat[i,18]<-AIC(exp.model.nocov.w.s,k = log(length(start )))
mat[i,24]<-AIC(logl.model.nocov.w.s,k = log(length(start )))























cox.model.nocov.w.m =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.w.m,method="breslow")
summary(cox.model.nocov.w.m )




































mat.m[i,6]<-AIC(cox.model.nocov.w.m,k = log(length(start )))
mat.m[i,12]<-AIC(weib.model.nocov.w.m,k = log(length(start )))
mat.m[i,18]<-AIC(exp.model.nocov.w.m,k = log(length(start )))
mat.m[i,24]<-AIC(logl.model.nocov.w.m,k = log(length(start )))





















cox.model.nocov.w.L =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.w.L,method="breslow")































mat.w.L[i,6]<-AIC(cox.model.nocov.w.L,k = log(length(start )))
mat.w.L[i,12]<-AIC(weib.model.nocov.w.L,k = log(length(start )))
mat.w.L[i,18]<-AIC(exp.model.nocov.w.L,k = log(length(start )))
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mat.w.L[i,24]<-AIC(logl.model.nocov.w.L,k = log(length(start )))



















dist.cens="weibull", beta=NA , x=NA)
data.frame(sim.data.nocov.e.s)
attach(sim.data.nocov.e.s)
cox.model.nocov.e.s =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.e.s,method="breslow")
































mat.e.s[i,6]<-AIC(cox.model.nocov.e.s,k = log(length(start )))
mat.e.s[i,12]<-AIC(weib.model.nocov.e.s,k = log(length(start )))
mat.e.s[i,18]<-AIC(exp.model.nocov.e.s,k = log(length(start )))
mat.e.s[i,24]<-AIC(logl.model.nocov.e.s,k = log(length(start )))
















dist.cens="weibull", beta=NA , x=NA)
data.frame(sim.data.nocov.e.m)
attach(sim.data.nocov.e.m)
cox.model.nocov.e.m =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.e.m,method="breslow")
































mat.e.m[i,6]<-AIC(cox.model.nocov.e.m,k = log(length(start )))
mat.e.m[i,12]<-AIC(weib.model.nocov.e.m,k = log(length(start )))
mat.e.m[i,18]<-AIC(exp.model.nocov.e.m,k = log(length(start )))
mat.e.m[i,24]<-AIC(logl.model.nocov.e.m,k = log(length(start )))
















dist.cens="weibull", beta=NA , x=NA)
data.frame(sim.data.nocov.e.L)
attach(sim.data.nocov.e.L)
cox.model.nocov.e.L =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.e.L,method="breslow")
































mat.e.L[i,6]<-AIC(cox.model.nocov.e.L,k = log(length(start )))
mat.e.L[i,12]<-AIC(weib.model.nocov.e.L,k = log(length(start )))
mat.e.L[i,18]<-AIC(exp.model.nocov.e.L,k = log(length(start )))
mat.e.L[i,24]<-AIC(logl.model.nocov.e.L,k = log(length(start )))











Simulation of log -logistic with no covariate
##################################################################
##################################################################







,z=list(c("unif", 0.8, 1.2)), dist.cens="llogistic", beta=NA , x=NA)
data.frame(sim.data.nocov.llg.s)
attach(sim.data.nocov.llg.s)



































mat.llg.s[i,6]<-AIC(cox.model.nocov.llg.s,k = log(length(start )))
mat.llg.s[i,12]<-AIC(weib.model.nocov.llg.s,k = log(length(start )))
mat.llg.s[i,18]<-AIC(exp.model.nocov.llg.s,k = log(length(start )))
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mat.llg.s[i,24]<-AIC(logl.model.nocov.llg.s,k = log(length(start )))




















cox.model.nocov.llg.m =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.llg.m,method="breslow")
summary(cox.model.nocov.llg.m )
































mat.llg.m[i,6]<-AIC(cox.model.nocov.llg.m,k = log(length(start )))
mat.llg.m[i,12]<-AIC(weib.model.nocov.llg.m,k = log(length(start )))
mat.llg.m[i,18]<-AIC(exp.model.nocov.llg.m,k = log(length(start )))
mat.llg.m[i,24]<-AIC(logl.model.nocov.llg.m,k = log(length(start )))


















dist.cens="llogistic", beta=NA , x=NA)
data.frame(sim.data.nocov.llg.L)
attach(sim.data.nocov.llg.L)
cox.model.nocov.llg.L =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.llg.L,method="breslow")
































mat.llg.L[i,6]<-AIC(cox.model.nocov.llg.L,k = log(length(start )))
mat.llg.L[i,12]<-AIC(weib.model.nocov.llg.L,k = log(length(start )))
mat.llg.L[i,18]<-AIC(exp.model.nocov.llg.L,k = log(length(start )))
mat.llg.L[i,24]<-AIC(logl.model.nocov.llg.L,k = log(length(start )))











simulation lognormal with no covariate
#################################################################




sim.data.nocov.LN.s= simple.surv.sim(n=21, foltime=3600, dist.ev=
c(’lnorm’),anc.ev=c(0.69978200185280),beta0.ev=c(5.84298525742252)
,anc.cens=1.17783687569519,beta0.cens=7.39773677281100,
z=list(c("unif", 0.8, 1.2)), dist.cens="lnorm", beta=NA, x=NA)
data.frame(sim.data.nocov.LN.s)
attach(sim.data.nocov.LN.s)
cox.model.nocov.LN.s =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.LN.s,method="breslow")
































mat.LN.s[i,6]<-AIC(cox.model.nocov.LN.s,k = log(length(start )))
mat.LN.s[i,12]<-AIC(weib.model.nocov.LN.s,k = log(length(start )))
mat.LN.s[i,18]<-AIC(exp.model.nocov.LN.s,k = log(length(start )))
mat.LN.s[i,24]<-AIC(logl.model.nocov.LN.s,k = log(length(start )))





















cox.model.nocov.LN.m =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.LN.m,method="breslow")






















































dist.cens="lnorm", beta=NA , x=NA)
data.frame(sim.data.nocov.LN.L)
attach(sim.data.nocov.LN.L)
cox.model.nocov.LN.L =coxph(Surv(stop , status) ~ 1,
data=sim.data.nocov.LN.L,method="breslow")















































Simulation of Cox no covariate
###################################################################
###################################################################
####### simulation of Cox censord time to event data(small data)
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sim.data.nocov.cox.s = sim.survdata(N=10, T=360, censor =.35,
num.data.frames = 1)
attach(sim.data.nocov.cox.s )
cox.model.nocov.cox.s =coxph(Surv(y, failed) ~ 1,
data=sim.data.nocov.cox.s$data ,method="breslow")

















































sim.data.nocov.cox.m = sim.survdata(N=150, T=360, censor =.35,
num.data.frames = 1)
attach(sim.data.nocov.cox.m )
cox.model.nocov.cox.m =coxph(Surv(y, failed) ~ 1,
data=sim.data.nocov.cox.m$data ,method="breslow")
































mat.cox.m[i,6]<-AIC(cox.model.nocov.cox.m,k = log(length(start )))
mat.cox.m[i,12]<-AIC(weib.model.nocov.cox.m,k = log(length(start )))
mat.cox.m[i,18]<-AIC(exp.model.nocov.cox.m,k = log(length(start )))
mat.cox.m[i,24]<-AIC(logl.model.nocov.cox.m,k = log(length(start )))
















cox.model.nocov.cox.L =coxph(Surv(y, failed) ~ 1,
data=sim.data.nocov.cox.L$data ,method="breslow")


























































c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.w.s)
attach(sim.data.cov.w.s)

























































mat1[i,57]<-summary(logNorm.model.cov.w.s )$ table[1,1] #coeff
mat1[i,58]<-summary(logNorm.model.cov.w.s )$ table[1,2] #std.err
mat1[i,59]<-summary(logNorm.model.cov.w.s )$ table[1,3]#statistic
mat1[i,60]<-summary(logNorm.model.cov.w.s )$ table[1,4] #p-val
mat1[i,61]<-summary(logNorm.model.cov.w.s )$ table[2,1] #coeff
mat1[i,62]<-summary(logNorm.model.cov.w.s )$ table[2,2] #std.err
mat1[i,63]<-summary(logNorm.model.cov.w.s )$ table[2,3]#statistic
mat1[i,64]<-summary(logNorm.model.cov.w.s )$ table[2,4] #p-val
mat1[i,65]<-summary(logNorm.model.cov.w.s )$ table[3,1] #coeff
mat1[i,66]<-summary(logNorm.model.cov.w.s )$ table[3,2] #std.err
mat1[i,67]<-summary(logNorm.model.cov.w.s )$ table[3,3]#statistic




mat1[i,14]<-AIC(cox.model.cov.w.s,k = log(length(start )))
mat1[i,27]<-extractAIC(weib.model.cov.w.s)[2];
mat1[i,28]<-AIC(weib.model.cov.w.s,k = log(length(start )))
mat1[i,41]<-extractAIC(exp.model.cov.w.s)[2];
mat1[i,42]<-AIC(exp.model.cov.w.s,k = log(length(start )))
mat1[i,55]<-extractAIC(logl.model.cov.w.s)[2];
mat1[i,56]<-AIC(logl.model.cov.w.s,k = log(length(start )))
mat1[i,69]<-extractAIC(logNorm.model.cov.w.s)[2];


















z=list(c("unif", 0.8, 1.2)), dist.cens="weibull", beta=list(c(-0.4),
c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.w.m)
attach(sim.data.cov.w.m)

























exp.model.cov.w.m=survreg(Surv(stop , status) ~ as.factor(x) + x.1,
dist="exp",data=sim.data.cov.w.m)
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mat1.cov.w.m[i,29]= summary(exp.model.cov.w.m )$ table[1,1]#coeff
mat1.cov.w.m[i,30]= summary(exp.model.cov.w.m )$ table[1,2]#std.err
mat1.cov.w.m[i,31]= summary(exp.model.cov.w.m )$ table[1,3]#statistic
mat1.cov.w.m[i,32]= summary(exp.model.cov.w.m )$ table[1,4]#p-val
mat1.cov.w.m[i,33]= summary(exp.model.cov.w.m )$ table[2,1]#coeff
mat1.cov.w.m[i,34]= summary(exp.model.cov.w.m )$ table[2,2]#std.err
mat1.cov.w.m[i,35]= summary(exp.model.cov.w.m )$ table[2,3]#statistic
mat1.cov.w.m[i,36]= summary(exp.model.cov.w.m )$ table[2,4]#p-val
mat1.cov.w.m[i,37]= summary(exp.model.cov.w.m )$ table[3,1]#coeff
mat1.cov.w.m[i,38]= summary(exp.model.cov.w.m )$ table[3,2]#std.err
mat1.cov.w.m[i,39]= summary(exp.model.cov.w.m )$ table[3,3]#statistic
mat1.cov.w.m[i,40]= summary(exp.model.cov.w.m )$ table[3,4] #p-val
































mat1.cov.w.m[i,14]<-AIC(cox.model.cov.w.m,k = log(length(start )))
mat1.cov.w.m[i,27]<-extractAIC(weib.model.cov.w.m)[2];
mat1.cov.w.m[i,28]<-AIC(weib.model.cov.w.m,k = log(length(start )))
mat1.cov.w.m[i,41]<-extractAIC(exp.model.cov.w.m)[2];
mat1.cov.w.m[i,42]<-AIC(exp.model.cov.w.m,k = log(length(start )))
mat1.cov.w.m[i,55]<-extractAIC(logl.model.cov.w.m)[2];






















z=list(c("unif", 0.8, 1.2)), dist.cens="weibull", beta=list(c(-0.4),











































































mat1.cov.w.L[i,14]<-AIC(cox.model.cov.w.L,k = log(length(start )))
mat1.cov.w.L[i,27]<-extractAIC(weib.model.cov.w.L)[2];
mat1.cov.w.L[i,28]<-AIC(weib.model.cov.w.L,k = log(length(start )))
mat1.cov.w.L[i,41]<-extractAIC(exp.model.cov.w.L)[2];
mat1.cov.w.L[i,42]<-AIC(exp.model.cov.w.L,k = log(length(start )))
mat1.cov.w.L[i,55]<-extractAIC(logl.model.cov.w.L)[2];
mat1.cov.w.L[i,56]<-AIC(logl.model.cov.w.L,k = log(length(start )))
mat1.cov.w.L[i,69]<-extractAIC(logNorm.model.cov.w.L)[2];













Simulation of exponential with covariate
####################################################################
####################################################################










c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.e.s)
attach(sim.data.cov.e.s)








































































mat1.cov.e.s[i,14]=AIC(cox.model.cov.e.s,k = log(length(start )))
mat1.cov.e.s[i,27]= extractAIC(weib.model.cov.e.s)[2];
mat1.cov.e.s[i,28]=AIC(weib.model.cov.e.s,k = log(length(start )))
mat1.cov.e.s[i,41]= extractAIC(exp.model.cov.e.s)[2];
mat1.cov.e.s[i,42]=AIC(exp.model.cov.e.s,k = log(length(start )))
mat1.cov.e.s[i,55]= extractAIC(logl.model.cov.e.s)[2];





















c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.e.m)
attach(sim.data.cov.e.m)
cox.model.cov.e.m =coxph(Surv(stop , status) ~ as.factor(x) + x.1,
data=sim.data.cov.e.m,method="breslow")
mat1.cov.e.m[i,5]= summary(cox.model.cov.e.m)$ coefficients[1,1]#coeff







mat1.cov.e.m[i,12]= summary(cox.model.cov.e.m )$ coefficients[2,5]#p-val














































mat1.cov.e.m[i,57]= summary(logNorm.model.cov.e.m )$ table[1,1]#coeff














mat1.cov.e.m[i,14]<-AIC(cox.model.cov.e.m,k = log(length(start )))
mat1.cov.e.m[i,27]<-extractAIC(weib.model.cov.e.m)[2];
mat1.cov.e.m[i,28]<-AIC(weib.model.cov.e.m,k = log(length(start )))
mat1.cov.e.m[i,41]<-extractAIC(exp.model.cov.e.m)[2];
mat1.cov.e.m[i,42]<-AIC(exp.model.cov.e.m,k = log(length(start )))
mat1.cov.e.m[i,55]<-extractAIC(logl.model.cov.e.m)[2];
























c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.e.L)
attach(sim.data.cov.e.L)
cox.model.cov.e.L =coxph(Surv(stop , status) ~ as.factor(x) + x.1,
data=sim.data.cov.e.L,method="breslow")





































































mat1.cov.e.L[i,14]<-AIC(cox.model.cov.e.L,k = log(length(start )))
mat1.cov.e.L[i,27]<-extractAIC(weib.model.cov.e.L)[2];
mat1.cov.e.L[i,28]<-AIC(weib.model.cov.e.L,k = log(length(start )))
mat1.cov.e.L[i,41]<-extractAIC(exp.model.cov.e.L)[2];
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mat1.cov.e.L[i,42]<-AIC(exp.model.cov.e.L,k = log(length(start )))
mat1.cov.e.L[i,55]<-extractAIC(logl.model.cov.e.L)[2];
mat1.cov.e.L[i,56]<-AIC(logl.model.cov.e.L,k = log(length(start )))
mat1.cov.e.L[i,69]<-extractAIC(logNorm.model.cov.e.L)[2];













Simulation of loglogistic with covariate
#################################################################
##################################################################









c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.llg.s)
attach(sim.data.cov.llg.s)





































































mat1.cov.llg.s[i,60]= summary(logNorm.model.cov.llg.s )$ table[1,4]#p-val





mat1.cov.llg.s[i,66]= summary(logNorm.model.cov.llg.s)$ table[3,2] #std.err
mat1.cov.llg.s[i,67]= summary(logNorm.model.cov.llg.s )$ table[3,3]#statistic
mat1.cov.llg.s[i,68]= summary(logNorm.model.cov.llg.s)$ table[3,4]#p-val
mat1.cov.llg.s[i,13]<-extractAIC(cox.model.cov.llg.s)[2];
mat1.cov.llg.s[i,14]<-AIC(cox.model.cov.llg.s,k = log(length(start )))
mat1.cov.llg.s[i,27]<-extractAIC(weib.model.cov.llg.s)[2];
mat1.cov.llg.s[i,28]<-AIC(weib.model.cov.llg.s,k = log(length(start )))
mat1.cov.llg.s[i,41]<-extractAIC(exp.model.cov.llg.s)[2];
mat1.cov.llg.s[i,42]<-AIC(exp.model.cov.llg.s,k = log(length(start )))
mat1.cov.llg.s[i,55]<-extractAIC(logl.model.cov.llg.s)[2];
mat1.cov.llg.s[i,56]<-AIC(logl.model.cov.llg.s,k = log(length(start )))
mat1.cov.llg.s[i,69]<-extractAIC(logNorm.model.cov.llg.s)[2];
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c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.llg.m)
attach(sim.data.cov.llg.m)





























































mat1.cov.llg.m[i,53]= summary(logl.model.cov.llg.m )$ table[3,3]#statistic
mat1.cov.llg.m[i,54]= summary(logl.model.cov.llg.m )$ table[3,4]#p-val







mat1.cov.llg.m[i,62]= summary(logNorm.model.cov.llg.m )$ table[2,2]#std.err








mat1.cov.llg.m[i,14]<-AIC(cox.model.cov.llg.m,k = log(length(start )))
mat1.cov.llg.m[i,27]<-extractAIC(weib.model.cov.llg.m)[2];
mat1.cov.llg.m[i,28]<-AIC(weib.model.cov.llg.m,k = log(length(start )))
mat1.cov.llg.m[i,41]<-extractAIC(exp.model.cov.llg.m)[2];
mat1.cov.llg.m[i,42]<-AIC(exp.model.cov.llg.m,k = log(length(start )))
mat1.cov.llg.m[i,55]<-extractAIC(logl.model.cov.llg.m)[2];
mat1.cov.llg.m[i,56]<-AIC(logl.model.cov.llg.m,k = log(length(start )))
mat1.cov.llg.m[i,69]<-extractAIC(logNorm.model.cov.llg.m)[2];








































































logl.model.cov.llg.L= survreg(Surv(stop ,status )~as.factor(x)+x.1,
dist="loglogistic",data=sim.data.cov.llg.L)
mat1.cov.llg.L[i,43]= summary(logl.model.cov.llg.L )$ table[1,1]#coeff
mat1.cov.llg.L[i,44]= summary(logl.model.cov.llg.L )$ table[1,2] #std.err
mat1.cov.llg.L[i,45]= summary(logl.model.cov.llg.L )$ table[1,3] #statistic
mat1.cov.llg.L[i,46]= summary(logl.model.cov.llg.L )$ table[1,4] #p-val
mat1.cov.llg.L[i,47]= summary(logl.model.cov.llg.L )$ table[2,1] #coeff
mat1.cov.llg.L[i,48]= summary(logl.model.cov.llg.L )$ table[2,2] #std.err
mat1.cov.llg.L[i,49]= summary(logl.model.cov.llg.L )$ table[2,3] #statistic
mat1.cov.llg.L[i,50]= summary(logl.model.cov.llg.L )$ table[2,4] #p-val
mat1.cov.llg.L[i,51]= summary(logl.model.cov.llg.L )$ table[3,1] #coeff
mat1.cov.llg.L[i,52]= summary(logl.model.cov.llg.L )$ table[3,2] #std.err
mat1.cov.llg.L[i,53]= summary(logl.model.cov.llg.L )$ table[3,3] #statistic
mat1.cov.llg.L[i,54]= summary(logl.model.cov.llg.L )$ table[3,4] #p-val






































Simulation of lognormal with covariate











c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.LN.s)
attach(sim.data.cov.LN.s)













































































mat1.cov.LN.s[i,68]<-summary(logNorm.model.cov.LN.s )$ table[3,4] #p-val
################## AIC
mat1.cov.LN.s[i,13]<-extractAIC(cox.model.cov.LN.s)[2];
mat1.cov.LN.s[i,14]<-AIC(cox.model.cov.LN.s,k = log(length(start )))
mat1.cov.LN.s[i,27]<-extractAIC(weib.model.cov.LN.s)[2];
mat1.cov.LN.s[i,28]<-AIC(weib.model.cov.LN.s,k = log(length(start )))
mat1.cov.LN.s[i,41]<-extractAIC(exp.model.cov.LN.s)[2];
mat1.cov.LN.s[i,42]<-AIC(exp.model.cov.LN.s,k = log(length(start )))
mat1.cov.LN.s[i,55]<-extractAIC(logl.model.cov.LN.s)[2];
mat1.cov.LN.s[i,56]<-AIC(logl.model.cov.LN.s,k = log(length(start )))
mat1.cov.LN.s[i,69]<-extractAIC(logNorm.model.cov.LN.s)[2];



















z=list(c("unif", 0.8, 1.2)), dist.cens="lnorm", beta=list(c(-0.4),


















































































mat1.cov.LN.m[i,14]<-AIC(cox.model.cov.LN.m,k = log(length(start )))
mat1.cov.LN.m[i,27]<-extractAIC(weib.model.cov.LN.m)[2];
mat1.cov.LN.m[i,28]<-AIC(weib.model.cov.LN.m,k = log(length(start )))
mat1.cov.LN.m[i,41]<-extractAIC(exp.model.cov.LN.m)[2];
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mat1.cov.LN.m[i,42]<-AIC(exp.model.cov.LN.m,k = log(length(start )))
mat1.cov.LN.m[i,55]<-extractAIC(logl.model.cov.LN.m)[2];
mat1.cov.LN.m[i,56]<-AIC(logl.model.cov.LN.m,k = log(length(start )))
mat1.cov.LN.m[i,69]<-extractAIC(logNorm.model.cov.LN.m)[2];



















beta=list(c(-0.4),c(0)), x=list(c("bern", 0.5), c("unif", 0.7, 1.3)))
data.frame(sim.data.cov.LN.L)
attach(sim.data.cov.LN.L)







































































mat1.cov.LN.L[i,14]<-AIC(cox.model.cov.LN.L,k = log(length(start )))
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mat1.cov.LN.L[i,27]<-extractAIC(weib.model.cov.LN.L)[2];
mat1.cov.LN.L[i,28]<-AIC(weib.model.cov.LN.L,k = log(length(start )))
mat1.cov.LN.L[i,41]<-extractAIC(exp.model.cov.LN.L)[2];
mat1.cov.LN.L[i,42]<-AIC(exp.model.cov.LN.L,k = log(length(start )))
mat1.cov.LN.L[i,55]<-extractAIC(logl.model.cov.LN.L)[2];
mat1.cov.LN.L[i,56]<-AIC(logl.model.cov.LN.L,k = log(length(start )))
mat1.cov.LN.L[i,69]<-extractAIC(logNorm.model.cov.LN.L)[2];












Simulation of Cox with covariate
##################################################




sim.data.cov.cox.s = sim.survdata(N=8, T=365, censor.cond=TRUE ,
censor =.35, num.data.frames = 1)
attach(sim.data.cov.cox.s )











































































mat1.cov.cox.s[i,66]= summary(logNorm.model.cov.cox.s)$ table[3,2] #std.err
mat1.cov.cox.s[i,67]= summary(logNorm.model.cov.cox.s)$ table[3,3]#statistic
mat1.cov.cox.s[i,68]= summary(logNorm.model.cov.cox.s )$ table[3,4]#p-val
################## AIC
mat1.cov.cox.s[i,13]<-extractAIC(cox.model.cov.cox.s)[2];
mat1.cov.cox.s[i,14]<-AIC(cox.model.cov.cox.s,k = log(length(start )))
mat1.cov.cox.s[i,27]<-extractAIC(weib.model.cov.cox.s)[2];
mat1.cov.cox.s[i,28]<-AIC(weib.model.cov.cox.s,k = log(length(start )))
mat1.cov.cox.s[i,41]<-extractAIC(exp.model.cov.cox.s)[2];
mat1.cov.cox.s[i,42]<-AIC(exp.model.cov.cox.s,k = log(length(start )))
mat1.cov.cox.s[i,55]<-extractAIC(logl.model.cov.cox.s)[2];
mat1.cov.cox.s[i,56]<-AIC(logl.model.cov.cox.s,k = log(length(start )))
mat1.cov.cox.s[i,69]<-extractAIC(logNorm.model.cov.cox.s)[2];
















sim.data.cov.cox.m = sim.survdata(N=1000, T=365, ,censor.cond=TRUE ,
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censor =.35, num.data.frames = 1)
attach(sim.data.cov.cox.m )




























































































mat1.cov.cox.m[i,14]<-AIC(cox.model.cov.cox.m,k = log(length(start )))
mat1.cov.cox.m[i,27]<-extractAIC(weib.model.cov.cox.m)[2];
mat1.cov.cox.m[i,28]<-AIC(weib.model.cov.cox.m,k = log(length(start )))
mat1.cov.cox.m[i,41]<-extractAIC(exp.model.cov.cox.m)[2];
mat1.cov.cox.m[i,42]<-AIC(exp.model.cov.cox.m,k = log(length(start )))
mat1.cov.cox.m[i,55]<-extractAIC(logl.model.cov.cox.m)[2];




















sim.data.cov.cox.L = sim.survdata(N=100000, T=360, censor =.35,
num.data.frames = 1)
attach(sim.data.cov.cox.L )




























































































k = log(length(start )))
extractAIC(weib.model.cov.cox.L)[2];AIC(weib.model.cov.cox.L,
k = log(length(start )))
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extractAIC(exp.model.cov.cox.L)[2];AIC(exp.model.cov.cox.L,
k = log(length(start )))
extractAIC(logl.model.cov.cox.L)[2];AIC(logl.model.cov.cox.L,
k = log(length(start )))
extractAIC(logNorm.model.cov.cox.L)[2];AIC(logNorm.model.cov.cox.L,












THE END OF SIMULATION CODES
##################################################
#####################################################










mean(age) ##over all mean sample
sd(age) ###over all standard deviation sample
range(age) ##over all range sample
length(age[event==1])### number of patients who died
length(age[event==0])### number of patients who survived
mean(age[event==1])### number of patients who died
sd(age[event ==1])### number of patients who died
range(age[event==1])### number of patients who died
mean(age[event==0])### number of patients who survived
sd(age[event ==0])### number of patients who survived





conf.int=F) #Kaplan Meier Graph for no covariate
cumfit = survfit(Surv(foltime ,even) ~ 1, data=cancer , type=’fleming ’)
plot(cumfit ,fun="cumhaz", xlab="Follow -Up Time (days)",conf.int=F,
ylab="Cumlative Hazard")##Kaplan -Meier Hazard Estimates
################ Fitting models and investigating best model
cox.real =coxph(Surv(foltime , even) ~ age+teletherapy+telebrachy ,
data=cancer ,method="breslow")
summary(cox.real )
weib.real= survreg(Surv(foltime , even) ~ age+teletherapy+telebrachy ,
data=cancer , dist="weibull")
summary(weib.real)




logl.real= survreg(Surv(foltime , even)~ age+teletherapy+telebrachy ,
data=cancer , dist="loglogistic")
summary(logl.real)








AIC(cox.real ,k = log(length(even )))
AIC(weib.real ,k = log(length(even )))
AIC(exp.real ,k = log(length(even )))
AIC(logl.real ,k = log(length(even )))
AIC(logNorm.real ,k = log(length(even )))
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############# Fitting cox model and checking assumptions
cox.real =coxph(Surv(foltime , even) ~ age+teletherapy+telebrachy ,
data=cancer ,method="breslow") fitting the full model
summary(cox.real )
test.ph = cox.zph(cox.real)#### testing proportional hazard assumption
test.ph
par(mfrow=c(1,1))
ggcoxzph(test.ph)##producing graphical for CPH assumption
ggcoxdiagnostics(cox.real ,type= "dfbeta",linear.predictions= FALSE ,
ggtheme = theme_bw()) ##chcking influential observation
ggcoxfunctional(Surv(foltime ,even)~age+log(age)+sqrt(age),
data=cancer)########### Checking nonlinearity
########### assesing overall model fit
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cox.snell =even - resid(cox.real ,type = "martingale")
coxph.res2 = survfit(Surv(cox.snell , even) ~ 1)
summary(coxph.res2)
Htilde = cumsum(coxph.res2$n.event / coxph.res2$n.risk)
plot(( coxph.res2$time), (Htilde), type = ’s’, col = ’red’,xlab="Time"
,ylab="Cumulative Hazard")
abline(0, 1, col = ’blue’, lty = 2)
par(mfrow=c(1,1))
################# Fitting individual covariate separately
cox.drug =coxph(Surv(foltime , even) ~ teletherapy+telebrachy ,
data=cancer ,method="breslow")
summary(cox.drug )
cox.age=coxph(Surv(foltime ,even)~age ,data=cancer ,method="breslow")
summary(cox.age )







cox.age2=coxph(Surv(foltime ,even)~ age2+teletherapy+telebrachy ,data=
cancer ,method="breslow")### full model of two categorical covariates
summary(cox.age2 )
test.ph = cox.zph(cox.age2) #### testing proportional hazard assumption
test.ph
cox.age.alone =coxph(Surv(foltime , even) ~ age2,
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